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I. INTRODUCTION 
Oral disintegrating tablets are solid single unit dosage forms that are placed on 
tongue, allowed to disperse or dissolve in saliva without the need of water, frequently 
releasing  of  the  drug  for  quick  onset  of  action.  Oral  disintegrating  tablets  are  well  
accepted by wide range of population especially as pediatric and geriatric patients 
who have difficulty in swallowing of conventional dosage forms. Some drugs are 
absorbed from mouth, pharynx and esophagus as saliva passes down to stomach. The 
bioavailability of such drug will be increase due to first pass metabolism
1
. 
Consumer satisfaction is the buzzword of the current millennium, and 
movement to achieve it has already begun in the pharmaceutical industry. An inability 
or un willingness to swallow solid oral dosage forms such as tablets and poor taste of 
medicine are some of the important reasons for consumer dissatisfaction. 
Recent developments in technology have presented viable alternatives for the 
patients who may have difficulty in swallowing tablets or liquids. Traditional tablets 
and capsules administered with an 8-oz. glass of water may be inconvenient or 
impractical for some patients. For example a very elderly patient may not be able to 
swallow  a  daily  dose  of  tablets.  An  eight  year  old  child  with  allergies  could  use  a  
more convenient dosage form of antihistamine syrup. A schizophrenic patient in the 
institution setting can hide a conventional tablet under his or her tongue to avoid his/ 
her daily dose of atypical antipsychotic. A middle-aged women undergoing radiation 
therapy for breast cancer may be too nauseous to swallow her H2-blocker
6
. 
To overcome these drawbacks, Orally disintegrating tablets (ODT) or Fast 
Dissolving Tablets (FDT)  has emerged as alternative oral dosage forms. These are 
novel types of tablets that disintegrate/dissolve/ disperse in saliva within few seconds. 
According to European Pharmacopoeia, the orally dispersible tablet should 
disperse/disintegrate in less than three minutes. The basic approach used in 
development of FDT is the use of super disintegrants like Crospovidone 
(Polyplasdone XL-10), Sodium starch glycolate (Primo gel, Explotab) and 
Pregelatinized starch (Starch-1500) etc., which provide instantaneous disintegration of 
tablet after putting on tongue, thereby releasing the drug in saliva.The bioavailability 
2 
of some drugs may be increased due to absorption of drugs in oral cavity and also due 
to pre gastric absorption of saliva containing dispersed drugs that pass down into the 
stomach. Moreover, the amount of drug that is subjected to first pass metabolism is 
reduced as compared to standard tablets
7
. 
Over the past three decades, ODT have gained much attention as a preferred 
alternative to conventional oral dosage forms such as tablets and capsules.  ODTis a 
solid dosage form that disintegrates and dissolves in the mouth (either on or beneath 
the tongue or in the buccal cavity) without water within 60 seconds or less
8
. The US 
Food and Drug Administration Center for Drug Evaluation and Research (CDER) 
defines in the Orange Book an ODT as “A solid dosage form containing medicinal 
substances, which disintegrates rapidly, usually within a matter of seconds, when 
placed upon the tongue. The European Pharmacopoeia however defines a similar 
term, that is fast dissolving tablet is a tablet that can be placed in the mouth where it 
disperses rapidly before swallowing
9
. 
 These tablets are distinguished from conventional sublingual tablets, lozenges, 
and buccal tablets which require more than a minute to dissolve in the mouth. In the 
literature, FDT are also called orally disintegrating, orodisperse, mouth-dissolving, 
quick-dissolve, fast-melt, and rapid-disintegrating tablets and freeze-dried 
wafers.FDTs release drug in the mouth for absorption through local oro mucosal 
tissues and through pregastric (e.g., oral cavity, pharynx, and esophagus), gastric (i.e., 
stomach),  and  postgastric  (e.g.,  small  and  large  intestines)  segments  of  the  
gastrointestinal  tract  (GIT).  Conventional  oral  dosage  forms  refers  to  tablets  and  
capsules that must be swallowed with water for dissolution, release, and absorption of 
the drug in the stomach and GIT distal sites. 
 Recent market studies indicate that more than half of the patient population 
prefers FDTs to other dosage forms and most consumers would ask their doctors for 
ODT (70%), purchase FDTs (70%), or prefer FDTs to regular tablets or liquids 
(>80%). These responses may, in part, be attributed to know ODT advantages such as 
ease of administration, ease of swallowing, pleasant taste, and the availability of 
several flavors. ODT also offer clinical advantages such as improved safety and in 
3 
some cases, improved efficacy and other broader indications
10
. FDT products have 
been developed for numerous indications ranging from migraines (for which a rapid 
onset of action is important) to mental illness (for which patient compliance is 
important for treating chronic indications such as depression and schizophrenia. 
 Dozens of FDT products have been launched worldwide over the past decades.  
All through these products have the Common characteristic of quick disintegration 
and dissolution when placed in the mouth in the presence of saliva, their physical 
attributes vary. For example, several techniques for making compressed tablets (e.g., 
Dura Solv, CIMA Labs, Eden  Prairie, MN; Ora Solv, CIMA Labs; and WOWTAB, 
Yamanouchi,  Norman,  OK)   that  are  easy  to  handle  and  can  be  packaged  in  blister  
packs or bottles. In contrast, some lyophilization manufacturing processes (e.g., 
Zydis, Cardinal Health, and Dublin, OH) produce fragile freeze-dried tablets and 
compressed multi particle tablets that can be packaged only in unit-dose blisters 
because of their high friability. 
 The administration of FDTs may not inherently result in a faster therapeutic 
onset, but it can circumvent problems such as difficulty in swallowing traditional 
solid oral dosage forms, particularly by paediatric and geriatric patients. Since FDTS 
dissolve quickly, they cannot provide controlled or sustained release, except those that 
contain slow-dissolving, microparticulate-coated drugs, which quickly disperse and 
are swallowed
5
. Fast dissolve tablets are in demand now-days because of their ability 
to release the medicament in fraction of minutes. There are particularly useful for 
treatment of conditions like hypertension and arthritic pain for obvious reasons
11
.  
Many patients find in difficult to swallow tablets and hard gelatin capsules and 
thus do not comply with prescription, which results in high incidence of non- 
compliance and ineffective therapy
6
. The aim of novel drug delivery system (NDDS) 
is to enhances safety and efficacy of drug molecule by formulating a convenient 
dosage form for administration and to achieve better patient compliance; one such 
approach is “fast dissolving tablets”
12-15
. Fast dissolving tablets are gaining 
importance as a potential drug delivery system. This dosage form dissolves and 
disintegrates in the oral cavity within minutes without need of water or chewing. This 
4 
formulation is useful in administration of drug in pediatric, geriatric patients and also 
in patients suffering from chemotherapy induced nausea and vomitting
16
. 
Most of the marketed fast dissolving tablets consists of non-steroidal anti-
inflammatory drugs e.g. Rofecoxib, Ketoprofen and anti hypertensive drugs e.g. 
Atenolol, Metoprolol, anti emetic drugs e.g. Ondansetron, Granisetron.Disintegrants 
can help to facilitable drug dissolution and subsequently improvement in 
bioavailability. Though starch is a good disintegrant it has some problems e.g. high 
levels required in formulation lack of compressibility which weakens the tablet 
structure
16
. Therefore, the need of development of a new disintegrant arises which 
eliminates all disadvantages that starch has. A number of disintegrants, known super 
disintegrants like sodium starch glycolate (Explotab), crospovidone (Polyplasdone 
XL), pregelatinized starch(Starch 1500) markedly improve tablet disintegrantion by 
swelling and or capillary action, cause tablet to break into fragments
17
.The efficiency 
of these super disintegrants in any fast dissolving dosage forms depend on its 
selection, concentrations methods of incorporation and steps used for preparation. 
Fast dissolving drug delivery is rapidly gaining acceptance as an important 
new drug delivery technology
18, 19
. Not all fast dissolving technologies actually 
dissolve; some use different disintegrants
13, 20
 and / or effervescent agents that cause 
the dosage form to disintegrate rapidly in the patients mouth within a minute and can 
be gulped easily without the need of water. Thus, it offers increase patients 
compliance and convenience. Patient convenience and compliance oriented research 
has resulted in bringing out many safer and newer drug delivery systems. Fast 
dissolving tablet is one such example with increased consumer choice, for the reason 
of rapid disintegration or dissolution self-administration even without water or 
chewing 
21-23
. 
ORAL DISINTEGRATING ( OR )FAST DISSOLVING TABLETA REVIEW 
Definition 
United States food and Drug Administration (FDA) defined Oral 
Disintegrating tablet (ODT) as “A solid dosage form containing medical substance or 
5 
active ingredient which disintegrates rapidly usually within a matter of seconds when 
placed upon the tongue
24
, prepared by direct compression method. “The disintegration 
time for ODTs generally ranges from several seconds to about a minute. 
 These are also known as melt-in-mouth tablets, repimelts, porous tablets, oro-
dispersible, quick dissolving or rapid disintegrating tablets. 
Advantages of fast dissolving drug delivery system
25
 
Ø Ease  of  administration  to  patients  who  refuse  to  swallow  a  tablet,  such  as  
paediatric and geriatric patients, mentally ill, disabled and uncooperative 
Ø Convenience of administration and accurate dosing as compared to liquids 
Ø No need of water to swallow the dosage from, which is highly convenient 
feature for patients who are traveling and do not have immediate access to 
water 
Ø Good mouth feels property of FDTs helps to change the basic view of 
medication as “Bitter pill”, particularly for pediatric patients 
Ø Ability to prove advantages than solid dosage form 
Ø Rapid dissolution of drug and absorption, which may produce rapid onset of 
action 
Ø Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva 
passes down into the stomach; in such cases bioavailability of drugs in 
increased 
Ø Pregastric absorption can result in improved bioavailability and as a result of 
reduced dosage, improved clinical performance through a reduction of 
unwanted effects (Figure No.1) 
 
6 
 
Figure No.1: Diagram showing advantages of FDTs
26 
Characteristics of fast dissolving drug delivery systems
27
 
a.  Ease of administration 
FDT are easy to administer and handle hence, leads to better patient 
compliance. Usually, elderly people experience difficulty in swallowing the 
conventional  dosage  forms  (Tablets  and  capsules)  because  of  tremors  of  extremities  
and dysphagia. Fast dissolving delivery systems may offer a solution for these 
problems. 
b. Taste of the medicament 
Orodispersible delivery systems usually contain the medicament in taste-
masked form. These delivery systems dissolve or disintegrate in patient’s mouth, thus 
releasing the active ingredients which come in contact with the taste buds and hence, 
taste masking of the drugs becomes critical to patient compliance. 
  
7 
c. Mouth feel 
 Mouth feel is critical, and patients should receive a product that feels pleasant. 
Any large particles from the disintegrating tablet that are insoluble or slowly soluble 
in saliva would lead to an unpleasant gritty feeling. This can be overcome by keeping 
the majority of the particles below the detectable size limit. In some cases, certain 
flavors can imbibe an improved mouth feel perception, resulting in a product that is 
perceived as being less gritty, even if the only change is the flavor. Effervescence can 
be added to aid disintegration and improve mouth feel by reducing the “dryness” of a 
products (Table No.1). 
Table No.1: Various therapeutic areas in which the Fast dissolving dosage forms 
are available
27
 
S.No Target population Therapeutic areas 
 
 
1 
 
 
 
 
Paediatric 
 
 
Antibiotics 
Anti-asthmatics 
Cough/cold/Allergy 
Anti-epileptics 
Analgesics/Antipyretics 
Antidepressants 
 
 
2 
 
 
 
Adult and Elderly 
 
Parkinson’s 
Antimigraine 
Alzheimer’s 
Anti-emetics 
Cancer 
Diabetes 
AIDS 
Gastric Relief 
Psychotherapeutics 
Cardiovascular 
Cough/ Cold/ Allergy 
Analgesics/ NSAIDS 
 
  
8 
INGREDIENTS COMMONLY USED IN FAST DISSOLVING TABLETS 
Super disintegrants
28
 
 Use of disintegrants is the basic approach in development of FDTs. 
Disintegrants play a major role in the disintegration and dissolution of FDT. It is 
essential  to  choose  a  suitable  disintegrant,  in  an  optimum  concentration  so  as  to  
ensure quick disintegration and high dissolution rates(Table No.2). 
Super disintegrants provide quick disintegration due to combined effect of 
swelling and water absorption by the formulation. Due to swelling of 
superdisintegrants, the wetted surface of the carrier increases, this promotes the 
wettability and dispersibility of the system, thus enhancing the disintegration and 
dissolution. The optimum concentration of the superdisintegrant can be selected 
according to critical concentration of disintegrant. Below this concentration, the tablet 
disintegration time is inversely proportional to the concentration of the 
superdisintegrant, whereas if concentration of superdisintegrant is above critical 
concentration, the disintegration time remains almost constant or even increases. 
 Sodium starch glycolate, Ac-di-sol (croscarmellose sodium), crospovidone, 
microcrystalline cellulose, pregelatinized starch are some of examples of super 
disintegrants. 
Table No.2: Popular Disintegrants used in Tablet 
S. 
No 
Disintegrants Mechanism 
Concentration 
% w/w 
1 Starch 
Disintegrate forms pathways throughout 
the tablet matrix that enable water to draw 
into the structure by capillary action, thus 
leading to disruption of tablet. 
5-20 
2 
Pregelatinized 
starch 
Responsible for increased dissolution rate 
from this tablet is rapid disintegration due 
to superior swelling capacity. 
5-15 
9 
S. 
No 
Disintegrants Mechanism 
Concentration 
% w/w 
 
3 
 
Sodium Starch 
Glycolate 
(Explotab and 
Primogel) 
Involves rapid absorption of water leading 
to an enormous increase in volume of 
granules result in rapid and uniform 
disintegration. 
1-3 
 
 
4 
 
 
Cross-linked 
polyvinyl 
Pyrrolidone (Cross 
Povidone, 
CrosspovidonM, 
Kollidon, 
Polyplasdone) 
The capillary activity of cross povidone for 
water is responsible for its tablet 
disintegration property. 
0.5-5 
 
5 
 
Cellulose (Ac-Di-
Sol, Nymce ZSX, 
PrimelloseSolutab) 
They show their ability to swell on contact 
with water results in rapid tablet 
disintegration. 
1-3 
 
6 
Microcrystalline 
Cellulose (Avicel) 
Allowing water to enter the tablet matrix 
by means of capillary pores, which break 
the hydrogen bonding between adjacent 
bundles of cellulose microcrystals and 
exhibit very good disintegrant property. 
10-20 
7 
Alginates (Alginic 
Acid, 
Satialgine) 
High affinity for water absorption and high 
sorption capacity make it an excellent 
disintegrant. 
1-5 
8 
 
Soy 
polysaccharides 
(Emcosoy) 
Natural super disintegrant, Rapid swelling 
in aqueous medium or wicking action. 
Does not contain any starch or sugar. Used 
in nutritional products. 
5-15 
9 
Gums (Guar 
Gums, Gum 
Karaya, Agar,    
Gellan Gum) 
As disintegrants because of their tendency 
to swell in water 
3-8 
10 
Chitin and 
Chitosan 
Moisture sorption and water uptake was 
found  the  major  mechanism  of  
disintegration while dissolution related to 
swelling capacity 
1-5 
10 
S. 
No 
Disintegrants Mechanism 
Concentration 
% w/w 
11 Smecta 
Their layered leaves like structure consist 
of aluminium and octahydral layers 
sandwiched between two tetrahydral silica 
layers. It has a large specific area and high 
affinity for water makes it good 
disintegrant. 
5-15 
12 Isapghula Husk 
Plantago ovata seeds husk has high 
swellability and gives uniform and rapid 
disintegration. 
5-15 
13 
Polacrillin 
Potassium 
It swells up at very fast rate upon contact 
with water or gastro intestinal fluid and act 
as an effective tablet disintegrant. 
10-20 
 
14 
 
Ion Exchange 
Resins 
Ambrelite IPR 88, 
Indion, Doshion 
Resins have ability to swell in the presence 
of water, showed disintegration of tablet. 
0.5-5 
15 
Gas–Evolving 
disintegrants 
(Citic Acid, Tatric 
Acid, Sodium Bi 
Carbonate) 
These react in contact with water to 
liberate carbon dioxide that disrupts the 
tablet. 
>10% 
 
Sugar based excipients
29
 
 Sugar based excipients are used for taste masking and as bulking agents. Most 
of the drugs are having unpleasant or bitter taste. And the basic requirement for 
designing FDTs is that the drug should not have disagreeable taste. So taste masking 
is necessary in most of the cases. Sorbitol, mannitol, xylitol, dextrose, fructose etc. are 
mainly used. Aqueous solubility and sweetness impart a pleasing mouth feel and good 
taste masking. But not all sugar-based materials have fast dissolution rate and good 
compressibility or compactability. However technologies are developed to make use 
11 
of the sugar based excipients in the design of fast dissolving tablets other ingredients 
commonly used are water soluble diluents, lubricants, plasticizers, binders, colors are 
flavors. 
Mechanism of action of superdisintegrants 
 
 
 
 
 
 
 
Figure No.2: Mechanism of action of superdisintegrants
5
 
By capillary action 
 Disintegration by capillary action is always the first step. When the tablet is 
placed into suitable aqueous medium, the medium penetrates into the tablet and 
replaces the air adsorbed on the particles, which weakens the intermolecular bond and 
breaks the tablet into fine particles. Water uptake by tablet depends upon 
hydrophilicity of the drug/excipient and on tableting conditions. For these types of 
disintegrants, maintenance of porous structure and low interfacial tension towards 
aqueous fluid is necessary which helps in disintegration by creating a hydrophilic 
network around the drug particles. 
By swelling 
 Perhaps the most widely accepted general mechanism of action for tablet 
disintegration is swelling the tablets with high porosity, show poor disintegration due 
to lack of adequate swelling force. On the other hand, sufficient swelling force is 
exerted  in  the  tablet  with  low  porosity.  It  is  worthwhile  to  note  that  if  the  packing  
 
12 
fraction is very high, fluid is unable to penetrate in the tablet and disintegration is 
again shows down (Figure No.3). 
 
 
Figure No.3: Disintegration of Tablet by wicking and swelling
26
 
By air expansion 
 When disintegrants with exothermic properties gets wetted, localized stress is 
generated due to capillary air expansion, which helps in disintegration of tablet. This 
explanation, however, is limited to only a few types of disintegrants and cannot 
describe the action of most modern disintegration agents. 
Due to release of gases 
 Carbon dioxide released within tablets on wetting due to interaction between 
bicarbonate and carbonate with citric acid or tartaric acid. The tablet disintegrates due 
to generation of pressure within the tablet. This effervescent mixture is used when 
pharmacist needs to formulate very rapidly dissolving tablets or fast disintegrating 
tablet. As these disintegrants are highly sensitive to small changes in humidity level 
and temperature, strict control of environment is required during manufacturing of the 
13 
tablets. The effervescent blend is either added immediately prior to compression or 
can be added onto two separate fraction of formulation.
26
 
By enzymatic reaction 
 Enzymes presents in the body also act as disintegrants. These enzymes destroy 
the binding action of binder and helps in disintegration. Actually due to swelling, 
pressure exerted in the outer direction or radial direction, it causes tablet to accelerate 
absorption of water leading to an enormous increase in the volume of granules to 
promote disintegration.
29
 
Due to particle repulsive forces 
 Another mechanism of disintegration attempts to explain the swelling of tablet 
made with non-swellable disintegrants. Guyot-Hermann has proposed a particle 
repulsion theory based on the observation that nonswelling particle also cause 
disintegration of tablets. The electric repulsive forces between particles are the 
mechanism  of  disintegration  and  water  is  required  for  it.  Researchers  found  that  
repulsion is secondary to wicking
13
(Figure No.4). 
 
Figure No.4: Disintegration by Deformation and repulsion
5 
Due to deformation 
 Hess had proved that during tablet compression, disintegrated particles get 
deformed and these deformed particles get into their normal structure when they come 
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in contact with water. Occasionally, the swelling capacity of starch was improved 
when granules were extensively deformed during compression. This increase in size 
of the deformed particles produces a breakup of the tablet. This may be a mechanism 
of starch as a superdisintegrant (Figure No.4). 
CRITERIA FOR FAST DISSOLVING DRUG DELIVERY SYSTEM
 
An ideal FDT should possess the following properties
29
 
ü Not require water to swallow, but it should dissolve or disintegrate in the 
mouth in matter of seconds 
ü Have a pleasing mouth feel 
ü Have an acceptable taste masking property 
ü Be harder and less friable 
ü Leave minimal or no residue in mouth after administration 
ü Exhibit low sensitivity to environmental conditions (temperature and 
humidity) 
ü Allow the manufacture of tablet by using conventional processing and 
packaging equipments 
FOLLOWING CONVENTIONAL TECHNIQUES ARE USED FOR 
PREPARATION OF FAST DISSOLVING DRUG DELIVERY SYSTEM
32
 
Disintegrant Addition  
Disintegrant addition technique is one of the popular techniques for 
formulating Fast-dissolving tablets because of its easy implementation and cost 
effectiveness. The basic principle involved in formulating Fast-dissolving tablets by 
disintegrant addition technique is addition of super disintegrants in optimum 
concentration so as to achieve rapid disintegration along with the good mouth feel. 
Freeze Drying 
 A process in which water is sublimated from the product after freezing. 
Lyophilization is a pharmaceutical technology, which allows drying of heat sensitive 
drugs and biological at low temperature under conditions that allow removal of water 
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by sublimation. Lyophilization results in preparations, which are highly porous, with a 
very high specific surface area, which dissolve rapidly and show improved absorption 
and bioavailability. 
Moulding  
 In this method, molded tablets are prepared by using water-soluble ingredients 
so  that  the  tablets  dissolve  completely  and  rapidly.  The  powder  blend  is  moistened  
with a hydro-alcoholic solvent and is molded into tablets under pressure lower than 
that used in conventional tablet compression. The solvent is then removed by air-
drying. Molded tablets are very less compact than compressed tablets. These possess 
porous structure that enhances dissolution. 
Sublimation  
 The slow dissolution of the compressed tablet containing even highly water 
soluble ingredients may be due to the low porosity of the tablets. Inert solid 
ingredients that volatilize readily (e.g. urea, ammonium carbonate, ammonium 
bicarbonate, hexa methelene tetramine, camphor etc.) were added to the other tablet 
ingredients and the mixture is compressed into tablets. The volatile materials were 
then removed via sublimation, which generates porous structures. Additionally, 
several solvents (e.g. cyclohexane, benzene) can be also used as pore forming agents 
(Figure No.5). 
 
 
 
 
 
 
Figure No.5:Sublimation technique for preparation of FDTs 
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Spray-Drying 
Spray drying can produce highly porous and fine powder that dissolve rapidly. 
The formulations are incorporated by hydrolyzed and non-hydrolyzed gelatins as 
supporting agents, mannitol as bulking agent, sodium starch glycolate or 
croscarmellose sodium as disintegrating agent and an acidic material (e.g. citric acid) 
and / or alkali material (e.g. Sodium bicarbonate) to enhance disintegration and 
dissolution. Tablet compressed from the spray dried powder disintegrated within 20 
seconds when immersed in an aqueous medium. 
Mass- Extrusion  
v Particles swell to precompression size and break up the matrix 
v Water is drawn into the pores and particles repel each other due to the 
resulting electrical force 
 This technology involves softening the active blend using the solvent mixture 
of water soluble polyethylene glycol, using methanol and expulsion of softened mass 
through the extruder or syringe to get a cylinder of the product and cut into even 
segments by using heated blade and to form tablets. The dried cylinder can also be 
subjected to coat the granules of bitter tasting drugs and thereby masking their bitter 
taste.  
Direct Compression
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 It is the easiest way to manufacture tablets. Conventional equipment, 
commonly available excipients and a limited number of processing steps are involved 
in direct compression. Also high doses can be accommodated and final weight of 
tablet can more easily be controlled than that of other production methods. Directly 
compressed tablet's disintegration and solubilization depends on single or combined 
action of disintegrants, water soluble excipients and effervescent agent. Disintegrant 
efficacy is strongly affected by tablet size and hardness, large and hard tablets have 
disintegration time more than that usually required. As consequences, products with 
optimal disintegration property often have medium to small size and/or high friability 
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and low hardness. Breakage of tablet edges during handling and tablet rupture during 
the opening of blister alveolus, all results from insufficient physical strength. 
Patented Technologies for Fast Disintegrating Tablets
34
 
Each technology has a different mechanism, and each fast-dissolving/ 
disintegrating dosage form varies regarding the following:  
· Mechanical strength of final product 
· Drug and dosage form stability 
· Mouth feel 
· Taste 
· Rate of dissolution of drug formulation in saliva 
· Swallow ability 
· Rate of absorption from the saliva solution and Overall bioavailability 
Zydis Technology 
 Zydis, the best known of the fast-dissolving/disintegrating tablet preparations 
was the first marketed new technology tablet. The tablet dissolves in the mouth within 
seconds after placement on the tongue. A Zydis tablet is produced by lyophilizing or 
freeze-drying the drug in a matrix usually consisting of gelatin. The product is very 
lightweight and fragile, and must be dispensed in a special blister pack. Patients 
should be advised not to push the tablets through the foil film, but instead peel the 
film back to release the tablet. The Zydis product is made to dissolve on the tongue in 
2 to 3 seconds. The Zydis formulation is also self-preserving because the final water 
concentration in the freeze-dried product is too low to allow for microbial growth
5
. 
Durasolv Technology  
 Durasolv is the patented technology of CIMA labs. The tablets made by this 
technology consist of a drug, fillers and a lubricant. Tablets are prepared by using 
conventional tableting equipment and have good rigidity. These can be packed into 
conventional packaging system like blisters. Durasolv is an appropriate technology 
for products requiring low amounts of active ingredients
6
.  
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Orasolv Technology 
 Orasolv Technology has been developed by CIMA labs. In this system active 
medicament is taste masked. It also contains effervescent disintegrating agent. Tablets 
are made by direct compression technique at low compression force in order to 
minimize oral dissolution time. Conventional blenders and tablet machine is used to 
produce the tablets. The tablets produced are soft and friable and packaged in 
specially designed pack and place system
7
. 
Flash Dose Technology 
 Flash dose technology has been patented by Fuisz. Nurofen meltlet, a new 
form of ibuprofen as melt-in-mouth tablets, prepared using flash dose technology is 
the first commercial product launched by Biovail Corporation. Flash dose tablets 
consist of self binding shearform matrix termed as "floss". Shearform matrices are 
prepared by flash heat process
28
. 
Wowtab Technology 
 Wowtab Technology is patented by Yamanouchi Pharmaceutical Co. WOW 
means "Without Water ". In this process, combination of low mouldability 
saccharides and high mouldability saccharides are used to obtain a rapidly melting 
strong tablet. The active ingredient is mixed with a low mouldability saccharide and 
granulated with a high mouldability saccharide and compressed into tablet
29
. 
Oraquick Technology
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The OraQuick fast-dissolving/disintegrating tablet formulation utilizes a 
patented taste masking technology. KV Pharmaceutical claims its microsphere 
technology, known as MicroMask, has superior mouthfeel over taste-masking 
alternatives
36
.  The  taste  masking  process  does  not  utilize  solvents  of  any  kind,  and  
therefore leads to faster and more efficient production. Also, lower heat of production 
than alternative fast-dissolving/disintegrating technologies makes OraQuick 
appropriate for heat-sensitive drugs. KV Pharmaceutical also claims that the matrix 
that surrounds and protects the drug powder in microencapsulated particles is more 
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pliable, meaning tablets can be compressed to achieve significant mechanical strength 
without disrupting taste masking. OraQuick claims quick dissolution in a matter of 
seconds, with good taste-masking.There are no products using the OraQuick 
technology currently on the market, but KV Pharmaceutical has products in 
development such as analgesics, scheduled drugs, cough and cold, psychotropics, and 
anti-infectives.  
Quick - Dis Technology
37
 
Lavipharm Laboratories Inc. (Lavipharm) has invented an ideal intraoral fast-
dissolving drug delivery system, which satisfies the unmet needs of the market. The 
novel intraoral drug delivery system, trademarked Quick-Dis™, is Lavipharm’s 
proprietary patented technology and is a thin, flexible, and quick-dissolving film. The 
film  is  placed  on  the  top  or  the  floor  of  the  tongue.  It  is  retained  at  the  site  of  
application and rapidly releases the active agent for local and/or systemic absorption. 
The Quick-Dis™ drug delivery system can be provided in various packaging 
configurations, ranging from unit-dose pouches to multiple-dose blister packages. 
The typical disintegration time, which is defined as the time at which the film 
begins to break when brought into contact with water, is only 5 to 10 seconds for the 
Quick-Dis™ film with a thickness of 2 mm. The dissolving time, which is defined as 
the time at which not less than 80% of the tested film is dissolved in aqueous media, 
is around 30 seconds for Quick Dis™ film with a thickness of 2 mm. The typical 
release profile of an active ingredient exhibited by a Quick-Dis™ drug delivery 
system is 50% released within 30 seconds and 95% within 1 minute.  
Nanocrystal Technology
37
 
For fast dissolving tablets, Elan's proprietary NanoCrystal technology can 
enable formulation and improve compound activity and final product characteristics. 
Decreasing particle size increases the surface area, which leads to an increase in 
dissolution rate. This can be accomplished predictably and efficiently using 
NanoCrystal technology. NanoCrystal particles are small particles of drug substance, 
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typically less than 1000 nanometers (nm) in diameter, which are produced by milling 
the drug substance using a proprietary wet milling technique. 
NanoCrystal™ Fast dissolving technology provides for:  
Ø Pharmacokinetic benefits of orally administered nanoparticles (<2 microns) in 
the form of a rapidly disintegrating tablet matrix 
Ø Product differentiation based upon a combination of proprietary and patent-
protected technology elements 
Ø Cost-effective manufacturing processes that utilize conventional, scalable unit 
operations 
Ø Exceptional durability, enabling use of conventional packaging equipment and 
formats (i.e., bottles and/or blisters) 
Ø Wide range of doses (up to 200mg of API per unit) 
Ø Use of conventional, compendial inactive components 
Ø Employment of non-moisture sensitive in actives 
NanoCrystal colloidal dispersions of drug substance are combined with water-
soluble GRAS (Generally Regarded as Safe) ingredients, filled into blisters, and 
lyophilized. The resultant wafers are remarkably robust, yet dissolve in very small 
quantities of water in seconds. This approach is especially attractive when working 
with highly potent or hazardous materials because it avoids manufacturing operations 
(e.g., granulation, blending, and tableting) that generate large quantities of aerosolized 
powder and present much higher risk of exposure. The freeze-drying approach also 
enables small quantities of drug to be converted into ODT dosage forms because 
manufacturing losses are negligible. 
Advantages of FDT 
Orodispersable tablets can offer several biopharmaceutical advantages such as 
improved efficiency over conventional dosage forms. For example, they require 
smaller amounts of active ingredient to be effective, improve absorption profiles, and 
offer better drug bioavailability than regular tablets and capsules. In addition, FDTs 
may be suitable for the oral delivery of drugs such as protein and peptide-based 
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therapeutics that have limited bioavailability when administered by conventional 
tablets. These products usually degrade rapidly in the stomach. Because drugs 
delivered in FDTs may be absorbed in the pregastric sites of highly permeable buccal 
and mucosal tissues of the oral cavity, they may be suitable for delivering relatively 
low-molecular weight and highly permeable drugs
32-36
. 
Future possibilities for improvements in FDTs and drug delivery are bright, 
but the technology is still relatively new. Several drug delivery technologies that can 
be leveraged on improving drug therapy from MDTs have yet to be fully realized
37, 38
. 
Table No.3: Some of Promising Drug Candidates for Fast Dissolving Tablets
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S.No Category Examples 
1 
Antibacterial 
agents 
Ciprofloxacin, tetracycline, erythromycin, rifampicin, 
penicillin, doxycyclin, nalidixic acid, trimethoprim, 
sulphacetamide, sulphadiazine etc. 
2 Anthelmintics 
Albendazole, mebendazole, thiabendazole, livermectin, 
praziquantel, pyrantel embonate, dichlorophen etc. 
3 Antidepressants 
Trimipramine maleate, nortriptyline HCl, trazodone HCl, 
amoxapine, mianserin HCl. 
4 Antidiabetics 
Glibenclamide, glipizide, tolbutamide, tolazamide, 
gliclazide, chlorpropamide etc. 
5 
Analgesics/anti-
inflammatory 
agents 
Diclofenac sodium, ibuprofen, ketoprofen, mefenamic 
acid, naproxen, oxyphenbutazone, indomethacin, 
piroxicam, phenylbutazone etc. 
6 Antihypertensives: 
Amlodipine, carvedilol, diltiazem, felodipine, minoxidil, 
nifedipine, prazosin HCl, nimodipine, terazosin HCl etc. 
7 Antiarrhythmics Disopyramide, quinidine sulphate, amiodarone HCl, etc. 
8 Antihistamines 
Acrivastine, cetrizine, cinnarizine, loratadine, 
fexofenadine, triprolidine etc. 
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S.No Category Examples 
9 
Anxiolytics, 
sedatives 
hypnotics and 
neuroleptics 
Alprazolam, diazepam, clozapine, amylobarbitone, 
lorazepam, haloperidol, nitrazepam, midazolam, 
phenobarbitone, thioridazine, oxazepam etc. 
10 Diuretics 
Acetazolamide, clorthiazide, amiloride, furosemide, 
spironolactone, bumetanide, ethacrynic acid etc. 
11 
Gastro-intestinal 
agents 
Cimetidine, ranitidine HCl, famotidine, domperidone, 
omeprazole, ondansetron HCl, granisetron HCl etc. 
12 Corticosteroids 
Betamethasone, beclomethasone, hydrocortisone, 
prednisone, prednisolone, methyl prednisolone etc. 
13 
Antiprotozoal 
agents 
Metronidazole, tinidazole, omidazole, benznidazole. 
 
Table No.4: Comparison of Fast Dissolving Techniques 
 
S. 
No 
ZYDIS (R.P. SCHERER, INC) 
Novelty Handling/Storage 
Drug 
release/bioavailability 
1 First to market Do not push tablet through foil Dissolves in 2 -10s 
2 Freeze Dried 
Do not use dosage form from   
damaged package 
Sensitive to degradation at 
humidities > 65% 
May allow for pre-gastric 
absorption leading to 
enhanced bioavailability 
ORASOLV (CIMA LABS, INC) 
1 
Unique taste 
masking 
 
Packaged in patented oil packs 
Disintegrates in 5 - 45s 
depending upon the size of 
the tablet 
2 
Lightly 
compressed 
No significant change in 
drug bioavailability 
23 
DURASOLV (CIMA LABS, INC) 
1 
Similar to Orasolv, 
but with 
better mechanical 
strength 
Packaged in foil or bottles 
Disintegrates in 5 - 45s 
depending upon the size of 
the tablet 
Package in bottles 
No significant change in 
drug bioavailability 
WOWTAB (YAMANOUCHI PHARMA TECHNOLOGIES, INC) 
1 
Compressed dosage 
form 
Avoid exposure to moisture or 
humidity 
Disintegrates in 5 - 45s 
depending upon the size of 
the tablet 
2 
Proprietary taste 
masking 
Avoid exposure to moisture or 
humidity 
Require specialized 
Packaging 
 
No significant change in 
drug bioavailability 
FLASHDOSE (FUISZ TECHNOLOGIES, LTD) 
1 
Unique spinning 
mech
m
 producing 
floss-like 
crystalline 
structure as cotton 
candy 
Avoid exposure to moisture and 
humidity 
Dissolves within 1 min 
Enhanced bioavailability 
FLASHTAB (PROGRAPHARM GROUP) 
 
1 
 
Compressed dosage 
form 
containing Drug as 
microcrystals 
__ Dissolves within 1 min 
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Table No.5: Marketed Fast Disintegrating Tablets
5, 28 
S. 
No 
Name of the Product Active Ingredients Company 
1 Feldene Fast, Melt Piroxicam Pfizer, USA 
2 Claritin Reditabs Loratidine 
Schering Plough Corp, 
USA 
3 Mazalit MTL Rizatritan Merckasnd Co. USA 
4 Zyprexia Olanzapine Eli Lilly, USA 
5 Nimulid-MD Nimesulide Panacea Biotech, India 
6 Pepcid RPD Famotidine Merck and Co., USA 
7 ZopranODT Ondansetron Glaxo Wellcome, UK 
8 Zooming – ZMT Zolmitriptan Astrazeneca, USA 
9 Zeplar TM Selegilline Amarin Corp, UK 
10 Torrox MT Rofecoxib 
Torrent Pharmaceutical, 
India 
11 Romilast Montelukast Ranbaxy Labs Ltd. India 
12 Mosid-MT Mosapride citrate 
Torrent Pharmaceutical, 
India 
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2. LITERATURE REVIEW 
Shetal Malke et.al.,
39 
Carried out the formulation and evaluation of Oxcarbazepine 
fast dissolve tablets. Fast dissolve tablets of oxcarbazepine were prepared containing 
avicel pH 102 (microcrystalline cellulose) as a diluent and Ac-Di-Sol (croscarmellose 
sodium) as a superdisintegrant by wet granulation process. The drug is poorly water-
soluble.  Hence  the  drug  release  was  tested  in  various  media  and  the  effect  of  
surfactant on drug release was studied. An effective pleasant tasting and stable 
formulation containing 12% Ac-Di-Sol, 25% Avicel pH 102 and 8.5 % starch as a 
binder was found to have a good hardness 4-4.5 kg/cm
2
, disintegration time of 28±5 
seconds and drug release of not less than 90% within 30 min.   
Mishra and Vijaya et.al.,
40
Carried out formulation of rapidly disintegrating tablets of 
Meloxicam using super disintegrants like sodium starch glycolate, Ac-Di-Sol and low 
molecular  weight  HPMC.  The  disintegration  time  in  the  oral  cavity  was  tested  and  
was found to be around 1 min. It was concluded that rapidly disintegrating tablets 
with proper hardness rapidly disintegrates in the oral cavity with enhanced dissolution 
rate. 
Rao et.al.,
41
Formulated immediate release tablets of Aceclofenac using different 
super disintegrants like sodium starch glycolate, starch1500, and Croscarmellose 
Sodium. The release profile of the drug in the formulation in various dissolution 
media such as 0.1 N HCl, 0.1 N HCl + 1% SLS (Sodium lauryl Sulphate) and 
phosphate buffer pH 7 was studied. The formulation containing sodium starch 
glycolate showed maximum drug release in different dissolution media. 
Kuchekar et.al.,
42
Formulated and evaluated mouth-dissolving tablets of 
Levofloxacin. Formulations were designed by factorial design technique. Sodium 
starch glycolate, Croscarmellose Sodium and treated agar were used as super-
disintegrates while microcrystalline cellulose was used as diluent. Direct compression 
technique was used, as it requires conventional tablet machinery and thus economical 
process. Formulations containing sodium starch glycolate along with other super-
disintegrates, showed rapid in-vitro and in-vivo dispersion time, as compared to other 
formulations. 
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D.M.Patelet.al.,
43
Performed Orodispersible tablets are better choice for the pediatric 
and geriatric patients. Present study demonstrates the use of factorial design in the 
formulation of orodispersible tablets of Rofecoxib. Preliminary screening of three 
superdisintegrants namely sodium starch glycolate, crospovidone and Croscarmellose 
Sodium was carried out (batches AA1 to AA9) and crospovidone was found most 
effective giving lowest disintegration time and wetting time. Batches AA10 to AA12 
were prepared to optimize the amount of crospovidone and the optimum 
concentration of crospovidone was found to be around 10%. From the preliminary 
results,  a  3
2
 full factorial design was employed for preparation of tablets possessing 
optimized characteristics (batches AA 13 to AA 21). The percentage of crospovidone 
(X1) and mannitol (X2) were selected as independent variables. Wetting time and 
disintegration  time  were  selected  as  dependent  variables  (response;  Y).  Full  and  
refined models were derived for the prediction of the response variable Y. Based on 
the results of multiple linear regression analysis, it was concluded that lower 
disintegration time and wetting time could be obtained when X1 is  kept at  high level 
and X2 is kept at low level. Promising batch (batch AA 18) was compared with two 
marketed samples (brand A and B) of rofecoxib tablets for in vitro drug release after 
30 min in three dissolution media. Tablets of batch AA 18 exhibited better drug 
dissolution after 30 min than the tablets of brand A and B in all the dissolution media. 
Yu-Chih Shen et.al.,
44
.Studied orally disintegrating Olanzapine for the treatment of a 
manic patient with esophageal stricture plus chronic pharyngitis. The case report 
shows that ODT(orodispersible tablet) olanzapine may be useful in the psychiatric 
management of manic and other patients for whom have an underlying medical 
condition they impedes swallowing oral medications. 
Mishra et.al.,
45
Formulated rapidly disintegrating oral tablet of valdecoxib using 
superdisitegrants following direct compression technique. It was concluded the fast 
disintegrating /dissolving tablet of the poorly soluble drug can be made by direct 
compression technique using selective superdisitegrants showing enhanced 
dissolution (i.e. improved bioavailability) and hence better patient compliance and 
effective therapy. 
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Shishu et.al.,
46
 Prepared tablets rapidly disintegrating in saliva containing bitter taste 
masked granules by compression method. The taste masked granules of 
Chlorpheniramine were prepared using aminoalkyl methacrylate copolymers 
(Eudragit E-100) by the extrution method. These taste masked granules were directly 
compressed into tablets using sodium starch glycolate as a superdisintegrant and 
evaluated for taste by both spectrophotometric method and through panel testing. 
Amin et.al.,
47
Formulated and evaluated Ofloxacin, a second-generation 
fluoroquinolone, is a bitter antibacterial. Taste masked adsorbates of ofloxacin were 
prepared using cationic exchange resins. Metronidazole benzoate, a less bitter salt of 
Metronidazole along with the taste-masked complex of Ofloxacin, was incorporated 
into palatable melt in mouth tablets, which are patient compliant. Taste evaluation of 
the tablets showed complete masking of the bitterness of Ofloxacin. Use of ion 
exchange resin as superdisintegrants was explored in melt in mouth tablets and a 
comparative study with existing superdisintegrants was carried out. The tablets were 
evaluated for various quality control parameters and they exhibited optimum 
physicochemical characteristics. In-vitro release studies revealed complete drug 
elution from the complex at pH 1.2. 
Pandey et.al.,
48
Carried out formulation and evaluation of Chloroquine 
phosphatetablets using three superdisintegrants,sodium starch glycolate, 
croscarmellose, crospovidone. The performance of three superdisintegrants was found 
out using intragranular and extragranular methods, both in the same quantity of 2% 
w/w. The study concluded that intragranular method of incorporation of disintegrants 
was better than extargranular method and Croscarmellose Sodium incorporated 
intragranular method gave better result than extragranular method. 
Lalla et.al.,
49
Prepared fast dissolving Rofecoxib tablets using Nymcel ZSX, Hyswell 
and Kollidon CL by two techniques viz. wet granulation with starch paste and direct 
compression. Both the formulations showed complete release of drug within 12 
minutes. 
Yyoshiteru watanabe et.al.,
50
Prepared rapidly disintegration tablet in saliva in the 
mouth by direct compression using microcrystalline cellulose, low-substituted 
28 
hydroxyl propyl cellulose showed rapid disintegration within 30 seconds was obtained 
in vitro using compounding ratios of microcrystalline cellulose to low-substituted 
hydroxy propyl cellulose. 
Akihiko et.al.,
51
 Developed an oral dosage form for elderly patients by using agar as 
base of rapidly disintegration oral tablets. The rapid disintegration of the treated agar 
tablets seemed due to be rapid water penetration into the tablet resulting from the 
large pore size and large overall pore volume. It was found that rapidly disintegrating 
oral tablets with proper hardness could be prepared using treated agar. 
Shirwaikaret.al.,
52
 Formulated Atenolol fast disintegrating tablet using three 
superdisintegrants croscarmellose sodium, crospovidone, and sodium starch glycolate 
by dry granulation method. Croscarmellose Sodium proved to be the best among the 
three and showed satisfactory results. 
Toshihiro Shimizu et.al.,
53
Carried out formulation study for Lansoprazole fast 
dissolving tablet containing enteric coated micro granules in which they studied effect 
of compression on dissolution behaviour. 
Mukesh Gohel et.al.,
54
Formulated mouth dissolving tablet of Nimesulide. Granules 
containing Nimesulide, camphor, crospovidone and lactose were prepared by wet 
granulation technique. Camphor was sublimed from the dried granules by exposure to 
vacuum. The porous granules were then compressed and evaluated. The result for 
obtaining a rapidly disintegrating dosage forms tablets should be prepared using an 
optimum concentration of camphor and a higher percentage of crospovidone.  
Mahajan et.al,.
55
Carried out formulation of mouth dissolving tablets of Sumatriptan 
succinate using super disintegrants like sodium starch glycolate,carboxy 
methylcellulose sodium, and treated agar by direct compression method. Almost 90% 
of drug was released from all formulation within 10 minutes. The formulation 
containing combination of sodium starch glycolate and carboxy methylcellulose was 
found to give the best results. 
Aithalet.al.,
56
Carried out formulation of fast dissolving tablets of Granisetron 
Hydrochloride using superdisintegrants by employing direct compression method. 
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Formulation containing crospovidone and Croscarmellose Sodium displayed shortest 
disintegration time compare to other disintegrants. 
Chaudhari et.al.,
57
Carried out formulation and evaluation of fast dissolving tablets of 
Famotidine by using different superdisintegrants (Ac-Di-Sol and Polyplasdone) with 
varying concentrations (2%, 3%, 4%, 5%). The bitter taste of Famotidine was masked 
using drug and eudragit E-100 in different ratios (1:1 – 1:10). The dissolution release 
rate was found to be 100% on four minutes. 
Devi et.al.,
58
Carried out formulation of orodispersible tablets of Fluconazole using 
two different volatilizable compounds viz. ammonium chloride and camphor by wet 
granulation method. Best formulation were chosen and compared with marketed 
conventional tablets. No significant difference between the technological properties of 
the prepared formulation and the marketed tablets. 
Sreenivas et.al.,
59
Carried out formulation and evaluation of mouth disintegrating 
tablets of ondansetron hydrochloride by direct compression method, by using 
disintegrants like crospovidone, Croscarmellose Sodium, pregelatinised starch, 
sodium starch glycolate that 10% disintegrate concentration was suitable for the 
preparation of ondansetron hydrochloride tablets containing disintegrant crospovidone 
and Croscarmellose Sodium were the best. 
Jinichi Fukami et.al.,
60
Formulated fast disitegrating compressed tablets using amino 
acid such as L-lysine HCl, L-alanine, Glycine, and L-tyrosine as disintegration 
accelerator. The tablet having hardness of about 4 kg/cm
2
.  The  wetting  time  of  the  
tablets increased in the order of L-lysine HCl. L-alanine, glycine and L-tyrosine. 
Whereas disintegration time in the oral cavity of the tablets increased in the order of 
L-alanine, glycine, L-lysine HCl, and L-tyrosine. When the polar component was 
small value, faster wetting of tablet was observed. When the dispersion component 
was small value, faster disintegration of tablet was observed except of L-tyrosine 
tablet. 
Fabio Baldiet.al.,
61
Carried out the studies on lansoprazole fast disintegrating tablet: 
A new formulation for an established proton pump inhibitor. Lansoprazole is a proton 
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pump inhibitor, which is an effective and well-tolerated treatment option in the 
management of acid related disorders. Lansoprazole fast disintegrating tablet (LFDT)- 
a new, patient friendly and more convenient formulation of lansoprazole, which can 
be taken with or without water, is the first PPI to be made available as an orally 
disintegrating tablet. Studies have shown that the bioavailability of LFDT is 
comparable to lansoprazole capsules, at both 15 and 13 mg doses, the indications and 
recommended dosages for LFDT are therefore identical to lansoprazole capsules. The 
new formulation may be of particular benefit to those with active life styles who do 
not always have water available, patients who have difficulty in swallowing and 
elderly patients.  
Saini et.al.,
62
Carried out the formulation of lamotrigine oro-dispersible tablets by 
superdisintegrating agents. Lamotrigine oro-dispersible tablets were formulated by 
using combination of low substituted hydroxypropylcellulose (10% w/w) and 
crospovidone (6% w/w) as superdisintegrating agents. Direct compression method 
was employed for the preparation of lamotrigine oro-dispersible tablets. The 
developed lamotrigine oro-dispersible tablets showed good taste and excellent feel 
and rapid dispersion in mouth. 
Na Zhao et.al.,
63
Studied functionally comparison of three classes of super 
disintegrants in promoting aspirin tablet disintegration and dissolution. The aim of the 
study  was  to  compare  the  disintegration  efficiency,  and  to  develop  a  discriminating  
test model for the three classes of super disintegrants represented by Ac-Di-Sol, 
primojel, and polyplasdone. Using a digital video camera to examine the 
disintegration process of tablets containing the same w/w percent concentration of the 
disintegrants, Ac-Di-Sol was found to disintegrate tablets rapidly into apparently 
primary particles, primojel also apparently disintegrated tablets into primary particles 
but more slowly, polyplasdone XL10 disintegrated tablets rapidly but into larger 
aggregated particles. The differences in the size distribution generated in the 
disintegrated tablets likely contribute to the drug dissolution rate differences found in 
aspirin tablets with similar disintegration rates.  
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Amrutkar et.al.,
64
Carriedout comparative evaluation of disintegrants by formulating 
Famotidine dispersible tablets by using various disintegrants like Croscarmellose 
Sodium, crospovidone, indion 414 and sodium starch glycolate was prepared with a 
view to increase its solubility. Among the four disintegrants added, the tablets 
prepared with Croscarmellose Sodium were superior with respect to disintegration 
and dissolution characteristics. 
Vikesh Shukla et.a.l.,
65
Carried out the formulation and evaluation of piroxicam 
dispersible tablets using natural disintegrants. The tablets of piroxicam was prepared 
by direct compression and wet granulation methods using starch paste as binder and 
superdisintegrants like isapgol husk, tragacanth, cassia tora. The dispersible tablet 
formulated using cross-linked tragacanth showed highest dissolution rate. Kinetic 
studies indicates that all the formulations followed first order release kinetics with 
diffusion mechanism. 
Chowdhary et.al.,
66
.Carried out effect of primogel and surfactants on the dissolution 
of piroxicam from capsule formulations. Piroxicam was formulated into capsules with 
primogel, tween 80, and SLS. The capsules were evaluated for drug content, 
disintegration and dissolution rate. The order of efficiency of these materials in 
increasing dissolution of piroxicam was found to be tween 80>SLS >primogel. They 
concluded as primogel and surfactants were found to increase the dissolution of 
piroxicam from capsule formulations.     
Basak et.al.,
67
Carried out studies in formulation of Ampicillin  dispersible tablets. 
Ampicillin dispersible  tablets were formulated employing superdisintegrating agents 
like sodium starchglycolate,microcrystalline cellulose and  starch.The tablets were 
prepared by wet granulation method.The tablets containing more quantity of sodium 
stachglycolate exhibited quick disintegration followed by tablets containg 
microcrystalline cellulose in a disintegrating mixture of sodiumstarchglycolate, 
microcrystalline cellulose and starch.It can be concluded that tablet prepared with  
sodium starch glycolate,micro crystalline cellulose,  starch in ratios 20mg:10mg:10mg 
per tablet with ethycellulose as granulating agent is promising for ampiciilin 
dispersible tablet. 
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Santanu Chakraborthyet.al.,
68
Studied the comparative study on effect of natural and 
synthetic superdisintegrants in the formulation of fast dissolving tablets.In the present 
study,the effect of natural superdisintegrants like isolated mucilage of plantago ovata 
and synthetic superdisintegrants like sodium starch glycolate and croscarmellose 
sodim were compared in the formulations of fast disintegrating tablets prepared by 
direct compression method using microcrystalline cellulose as direct compressible 
vehicle.Tablets were evaluated for weight variation, hardnees,disintegration test,drug 
content,friability,dissolution,swelling index.They are concluded that among all 
superdisintegrants,plantago ovata mucilage showed the highest swelling index and 
better disintegrating property than synthetic superdisintegrants. 
Raghavan et.a.l.,
69
 Studied the effect of Aspirin on pharmacokinetics of piroxicam in 
healthy male volunters. The influence of aspirin on the pharmacokinetics and 
pharmacodynamics of piroxicam is not known. The study indicates that 
pharmacokinetic parameters Cmaxand Tmax are not altered on concurrent administration 
of aspirin. 
Ramaraoet.al.,
70
Carried out the improvement of dissolution rate and bioavailability 
of piroxicam with pregelatinizwd starch. Piroxicam dispersions in pregelatinized 
starch (PGS) were prepared in different drug and carrier ratios and were characterized 
byX-raydiffractograms (XRD), differential scanningcalorimetry (DSC).  They 
observed that all the tablets formulated with piroxicam pregelatinized starch physical 
mixtures, dispersions were found to contain piroxicam within 100±5% of the labelled 
claim. Finally concluded that fast disintegrating tablets giving rapid dissolution of the 
drug could be formulated employing piroxicam pregelatinized starch dispersions by 
conventional wet granulation method. 
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3. AIM AND OBJECTIVE  
Need of the present work 
            For the past two decades, there has been enhanced demand for more patient 
compliance dosage forms. As a result, the demand for their technologies has been 
increasing three fold annually. Since the development cost of a new chemical entity is 
very high, the pharmaceutical companies are focusing on the development of new 
drug delivery systems for existing drug with an improved efficacy and bioavailability 
together with dosing frequency to minimize side effects. 
v This results in slower dissolution and absorption rates on oral administration 
and is one of the causes of gastro intestinal side effects  
v Improvement in drug solubility expected to enhance its bioavailability and 
reduce local side effects 
Difficulty in swallowing (dysphasia) is a common problem of all age groups, 
especially the elderly and pediatrics, because of physiological changes associated with 
these groups. Other categories also several problems in using conventional oral 
dosage forms include the mentally ill, uncooperative patients suffering from nausea, 
sudden episodes of allergic attack or coughing. Sometimes it may be difficult to 
swallow conventional products due to nonavailability of water. These problems led to 
the development of levofloxacin as mouth dissolving tablets. Which disintegrate and 
dissolve in saliva without the need of drinking water. The saliva serves to rapidly 
disperse  the  dosage  form  and  the    dissolved  medicament  is  swallowed  along  with  
saliva in normal way. As the dissolved medicaments along with saliva passes down 
into stomach, they are absorbed from the mouth, pharynx, and oesophagus. Therefore 
the bioavailability of levofloxacin is significantly greater than those observed from 
conventional levofloxacin dosage forms.   
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4. PLAN OF WORK 
Levofloxacin is an antibiotic used for treatment of a number of infections 
including infection of joints and bones, gastroenteritis, malignant otitis externa, 
respiratory tract infections, cellulities, urinary tract infections, anthrax, skin structural 
infections, typhoid fever and it also used in treatment of community acquired 
pneumonia, chronic bacterial prostitis, nosocomial pneumonia etc. 
v It has prolonged half-life about 8 hrs  
v It is poorly water soluble drug  
v When a poorly water soluble drug administered orally it may cause problems 
in bioavailability and dissolution rates due to its poor solubility in biological 
fliuds  
v Hence  the  present  work  was  aimed  at  increasing  the  rate  of  dissolution  of  
Levofloxacin thus providing faster rate of absorption by adding potential 
superdisintegrants like croscarmellose sodium, crospovidone, and sodium 
starch glycolate in different concentrations  
v To mask the bitter taste of Levofloxacin, Saccharin sodium was used as 
sweetening agent  
v Seven formulations of orodispersible tablets of Levofloxacin were prepared 
using three different super disintegrants namely croscarmellose sodium, 
crospovidoneand sodium starch glycolate with three concentrations prepared 
by direct compression method  
v The prepared Levofloxacin orodispersible tablets using different 
concentrations were evaluated by invitro drug release studies 
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The study was planned to carry out as follows: 
               Preparation of seven formulations of orodispersible tablets of 
Levofloxacinby using different superdisintegrants in three different concentrations. 
1. Evaluation study of powder mixed blend of drug and excipients: 
Ø Angle of repose 
Ø Bulk density 
Ø Tapped density 
Ø Compressibility index 
Ø Hausner ratio 
2. Drug and excipients interaction studies by FTIR. 
3. Compression of tablets by “Direct Compression method”. 
4. Evaluation of tablets: 
v Weight variation 
v Hardness 
v Thickness 
v Friability 
v Disintegration time 
v Estimation of drug content 
v Water absorption test. 
5. In-vitro drug release studies. 
6. Stability studies 
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5. DRUG PROFILE 
LEVOFLOXACIN
71
 
 
CHEMICAL DATA  
 Chemical name : (-)-(s)-9_fluoro 2,3-dihydro 3-methyl 10 (4-methyl-1- 
   Piperazinyl 7-oxo- 7 Pyridol (1, 2, 3 De)-1,4 
   Benzoxazine 6- carboxylic acid hemihydrate 
 Formula :  C18 H2O F N3O4 .½ H2O 
 Molecular mass : 331.37 g/mol 
PHYSICAL DATA 
 Solubility     : Freely soluble at pH range of 0.6 to 5.8 and it shows 
   Maximum solubility at pH 6.7 
 Melting point : 214-216° C 
 Drug Category : Fluoroquinolones                                                                                                    
PHARMACOKINETIC DATA 
 Absorption : Rapidly and well absorbed from GIT with peak 
plasma Concentration    
 Bioavailability :  99% 
 Half life : 6-8 hours 
 Distribution : Bile (high concentration) ,CSF(10%) ,crosses 
placental  barrier 
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 Protein binding : 24-38% 
 Metabolism : Hepatic including CYP A2 
 Excretion : Renal (major), non renal routes like hepatic, billiary, 
transluminal Secretion 
Mechanism of Action
72
 
Levofloxacin Hcl drug has invitro activity  against  a  wide  range  of  Gram  
negative and Gram positive organism. Levofloxacin inhibits bacterial DNA gyrase, an 
enzyme responsible for countering excessive supercoiling of DNA during replication 
of transcription. Levofloxacin also inhibits a type 2 topoisomerase and isomerise 
which leadsto inhibition of cell division in infective microorganism. 
Uses
73
 
Levofloxacin is used for treatment of a number of infections including 
infection of joints and bones, gastroenteritis, malignant otitis externa, respiratory tract 
infections, cellulities, urinary tract infections, anthrax, skin structural infections, 
typhoid fever and italso used in treatment of community acquired pneumonia, chronic 
bacterial prostitis,nosocomial pneumonia etc. 
Brand Names - Levaquin, Adlox, Aflevo etc 
Available Dosages - Tablets, Intravenous and ophthalmic solutions   
Dosing - Adult dose is 250-750mg (immediate release tablets) for 
Every 12hours or 500-1000mg (extended release tablets),                                                
200-400mg (i.v), Child dose is 250 mg/kg bid. 
Contraindications 
Levaquin administration may become contraindicated in some patientswith a 
history of hypersensitivity to Levofloxacin and it also contraindicated in patients 
withepilepsy and other seizure disorders. 
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Pregnancy 
Levofloxacin comes under pregnancy category C where there is no 
evidencestudies of Levofloxacin in pregnant women so it   should not used during 
pregnancy. 
Nursing Mothers 
Levofloxacin should avoid in nursing women. 
Pedriatic population 
Levofloxacin should not used in infants as they have not developedsufficient 
enzymes to metabolise drug and it should not used to children via intravenous route. 
Adverse reactions
74
 
Levofloxacin may cause mild adverse reactions like nausea, 
vomiting,diarrhoea,rashes, abnormal liver functions and it may cause some rare but 
serious adverse effects like Myasthenia gravis including muscle weakness, breathing 
problem,neuropathy,photosensitivity reactions etc. 
Drug Interaction 
Levofloxacin may interact with some drugs as well as a herbal and natural 
supplements. Levofloxacin also interacts with NSAIDS causes Black box warning 
which leads to Achiles tendon rupture.It also interact with theophylline and this 
interaction may increases the risk of cardiotoxicity, arrhythmias and anticoagulation. 
Storage 
Oral products should be stored at 5-25
0
C, Ophthalmic products should be 
stored  At 2-25 C intravenous solutions should be stored at 25
0
C. 
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6.  A GENERAL PROFILE ONSUPER DISINTEGRANTS AND 
EXCIPIENTS USED IN THE STUDY 
Bioavailability of a drug depends upon the absorption of the drug, which is 
affected by solubility of the drug in gastrointestinal fluid and permeability of the drug 
across gastrointestinal membrane. Use of super disintegrants is the basic approach in 
development of fast disintegration tablets. Super disintegrants play a major role in the 
disintegration and dissolution of ODT. It is essential to choose a suitable super 
disintegrant, in an optimum concentration so as to ensure quick disintegration and 
high dissolution rates. Superdisintegrants provide quick disintegration due to 
combined effect of swelling and water absorption.Due to swelling of 
superdisintegrants, the wetted surface of the tablet increases and thus promotes 
disintegration and dissolution the drug in the formulation
75
. 
 
Figure No.6: Tablet disintegration and subsequent drug dissolution 
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SODIUM STARCH GLYCOLATE
 
General description
76
 
Nonproprietary Names 
BP   : Sodium starch glycollate 
USP NF : Sodium starch glycolate 
Synonyms 
Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; Primojel; 
starch Carboxymethyl ether, sodium salt; Tablo. 
Chemical Name   
Sodium carboxymethyl starch   
Structural Formula 
 
Functional Category 
Tablet and capsule disintegrant. 
Applications in Pharmaceutical Formulation or Technology
77 
Sodium starch glycolate is widely used in oral pharmaceuticals as a 
disintegrant in capsule and tablet formulations. It is commonly used in tablets 
prepared by either direct-compression or wet-granulation processes. The usual 
concentration employed in a formulation is between 2% and 8%, with the optimum 
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concentration about 4%, although in many cases 2% is sufficient.Disintegration 
occurs by rapid uptake of water followed by rapid and enormous swelling.Although 
the effectiveness of many disintegrants is affected by the presence of hydrophobic 
excipients such as lubricants, the disintegrant efficiency of sodium starch glycolate is 
unimpaired. Increasing the tablet compression pressure also appears to have no effect 
on disintegration time.Sodium starch glycolate has also been investigated for use as a 
suspending vehicle.  
Description
78
 
Sodium starch glycolate is a very fine, white or off white,free flowing powder, 
odourless.   
Typical Properties 
Alkalinity : pH 3-5 % or pH =5.5-7.5 %. For a 3.3% aqueous dispersion. 
Density (bulk)  : 0.756 g/cm
3 
Density(tapped) :  0.945 g/cm
3
 
Solubility 
Sparingly soluble in ethanol (95%), practically insoluble in water. 
Stability and Storage Conditions
 
Tablets prepared with sodium starch glycolate have good storage properties. 
Sodium starch glycolate is stable and should be stored in a well-closed container in 
order to protect it from wide variations of humidity and temperature, which may cause 
caking.The physical properties of sodium starch glycolate remain unchanged for up to 
3-5 years if it is stored at moderate temperatures and humidity. 
Safety
 
Sodium starch glycolate is widely used in oral pharmaceutical formulations 
and is generally regarded as a nontoxic and nonirritant material. However, oral 
ingestion of large quantities may be harmful. 
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CROSPOVIDONE  
GENERAL DESCRIPTION
78
 
Nonproprietary Names 
BP   : Crospovidone 
USP NF : Crospovidone 
Synonyms 
Crosslinked povidone; E1202; Kollidon CL; Kollidon CL-M; Polyplasdone 
XL; Polyplasdone XL-10; polyvinylpolypyrrolidone; PVPP; 1-vinyl-2-pyrrolidinone 
homopolymer. 
Chemical Name  
1-Ethenyl-2-pyrrolidinone homopolymer  
Empirical Formula (C6H9NO)n 
Molecular Weight1,000,000 
The USPNF 23 describes crospovidone as a water-insoluble synthetic 
crosslinked homopolymer of N-vinyl-2-pyrrolidinone. An exact determination of the 
molecular weight has not been established because of the insolubility of the material. 
Structural Formula 
 
Functional Category 
 Tablet disintegrant. 
43 
Applications in Pharmaceutical Formulation or Technology
79 
Crospovidone is a water-insoluble tablet disintegrant and dissolution agent 
used at 2-5% concentration in tablets prepared by direct-compression or wet- and  
dry-granulation methods. It rapidly exhibits high capillary activity and pronounced 
hydration capacity, with little tendency to form gels. Studies suggest that the particle 
size of crospovidone strongly influences disintegration of analgesic tablets. Larger 
particles provide a faster disintegration than smaller particles. Crospovidone can also 
be used as a solubility enhancer. With the technique of co-evaporation, crospovidone 
can be used to enhance the solubility of poorly soluble drugs. The drug is adsorbed on 
to  crospovidone  in  the  presence  of  a  suitable  solvent  and  the  solvent  is  then  
evaporated. This technique results in faster dissolution rate. 
Description 
 
Crospovidone is a white to creamy-white, finely divided, free-flowing, 
practically tasteless, odorless or nearly odorless, hygroscopic powder. 
Typical Properties 
Acidity or Alkalinity :   pH =5.0-8.0. %(1% w/v aqueous slurry) 
Density (bulk) :   0. 363 g/cm
3 
Density (tapped) : 0. 543 g/cm
3
 
Solubility 
 Practically insoluble in water and most common organic solvents.   
Stability and Storage Conditions
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Since crospovidone is hygroscopic, it should be stored in an airtight container 
in a cool, dry place. 
Safety 
Crospovidone is used in oral pharmaceutical formulations and is generally 
regarded as a nontoxic and nonirritant material. 
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CROSCARMELLOSE SODIUM
 
General Description
76
 
Nonproprietary Names 
BP   : Croscarmellose Sodium 
USP NF : Croscarmellose Sodium 
Synonyms 
Ac-Di-Sol; crosslinked carboxymethylcellulose sodium; Explocel; modified 
cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; Vivasol. 
Chemical Name   
Cellulose, carboxymethyl ether, sodium salt. 
 Empirical Formula and Molecular Weight 
Croscarmellose Sodium is a crosslinked polymer of carboxymethylcellulose 
sodium. The USP 28 describes carboxymethylcellulose sodium as the sodium salt of a 
polycarboxymethyl ether of cellulose. Typical molecular weight is 90 000-700 000. 
Structural Formula 
. 
Functional Category 
Tablet and capsule disintegrant. 
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Applications in Pharmaceutical Formulation or Technology
80
 
Croscarmellose Sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets, and granules.In tablet formulations, Croscarmellose 
sodium may be used in both direct-compression and wet-granulation processes. When 
used in wet granulations, the Croscarmellose sodium should be added in both the wet 
and dry stages of the process (intra- and extragranularly) so that the wicking and 
swelling ability of the disintegrant is best utilized.Croscarmellose Sodium at 
concentrations up to 5% w/w may be used as a tablet disintegrant, although normally 
2% w/w is used in tablets prepared by direct compression and 3% w/w in tablets 
prepared by a wet-granulation process. 
Description 
Croscarmellose Sodium occurs as an odorless, white or grayish-white powder. 
Typical Properties 
Acidity or Alkalinity :   pH =5.0-7.0 % (1% w/v solution in Co2 free water) 
 Density (bulk) :  0. 529 g/cm
3 
 Density (tapped) : 0. 819 g/cm
3
 
Solubility 
 Practically insoluble in water. Although, swells rapidly 4-8 times its original 
volume on contact with water. 
Stability and Storage Conditions
81 
Croscarmellose sodium is a stable through hygroscopic material.A model tablet 
formulation prepared by direct compression, with croscarmellose sodium as a 
disintegrant, showed no significant difference in drug dissolution after storage at 30°C for 
14 months.Croscarmellose sodium should be stored in a well-closed container in a cool, 
dry place. 
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Safety 
Croscarmellose sodium is mainly used as a disintegrant in oral pharmaceutical 
formulations and is generally regarded as an essentially nontoxic and nonirritant 
material. However, oral consumption of large amounts of croscarmellose sodium may 
have a laxative effect, although the quantities used in solid dosage formulations are 
unlikely to cause such problems. 
In the UK, croscarmellose sodium is accepted for use in dietary supplements. 
The WHO has not specified an acceptable daily intake for the related substance 
carboxy methyl cellulose sodium, used as a food additive, since the levels necessary 
to achieve a desired effect were not considered sufficient to be a hazard to health.
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MICROCRYSTALLINE CELLULOSE 
Structural formula 
 
GENERAL DESCRIPTION
76
 
Nonproprietary Name 
Microcrystalline cellulose 
Synonym    
Avicel 
Empirical formula   
(C6 H10 O5) n 
Molecular weight  
36,000 
Specific surface area  
1.21-1.30 m
2
/g 
Nominal mean particle size 
100 µm 
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Pharmaceutical applications
82 
Avicel is widely used in pharmaceuticals, primarily as a binder or diluent in 
oral tablet and capsule formulation where it is used both in wet granulation as well as 
direct compression processes. In addition to its use as a binder or diluent it also has a 
disintegrant and lubricant property that makes it useful in tabletting. 
Pharmaceutical applications of Avicel 
Use Concentration (%) 
Adsorbent 20 – 90 
Anti-adherent 5 – 20 
Capsule diluent 20 – 90 
Tablet disintegrants 5 – 15 
Tablet binder/ Diluent 20 – 90 
 
Description 
 
Avicel is purified, partially depolymerised cellulose that occurs as a white, 
odorless, tasteless, crystalline powder composed of porous particles. It is 
commercially available in different particle sizes and moisture grades, which have 
different properties and applications. 
Typical Properties 
Acidity or Alkalinity :   5-7.5      
 Density(bulk) :  0.337 g/cm 
3 
 Density (tapped) : 0. 478 g/cm 
3 
Melting Point  : Chars at 260
0
C – 270
0
C  
Solubility 
practically insoluble in water, dilute acids and most organic solvents. Slightly 
soluble in 5%w/v sodium hydroxide solution. 
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Functional Category 
Adsorbent, tablet and capsule diluent, tablet disintegrant. 
Stability and storage conditions
83 
Avicel is a stable though hygroscopic material. The bulk material should be 
stored in a well closed container in a cool, dry place. 
Safety
 
It is generally regarded as a nontoxic and nonirritant material. It is not 
absorbed systemically and thus has little toxic potential. Deliberate abuse of 
formulations containing cellulose as inhalation has resulted in formation of cellulose 
granulomas. 
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MANNITOL 
Structural formula 
 
GENERAL DESCRIPTION
78
 
Empirical formula 
C6H14O6 
Molecular weight 
182.17 
Melting point 
166-168
0
C 
Functional category  
Sweetening agent, tablet and capsule diluent, tonicity agent, vehicle (vehicle 
agent) for lyophilized preparation. 
Applications in Pharmaceutical Formulation or Technology
84 
 In Pharmaceutical preparation, it is primarily used as diluent (10-90%) in 
tablet formulations.
 
Description 
Mannitol occurs as white, odorless, crystalline powder, or free flowing 
granules. It has sweet taste, approximately sweet as glucose. 
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Typical Properties 
 Density (bulk) :   0. 430 g/cm 
3 
 Density (tapped) : 0. 734g/cm 
3
 
Solubility 
 In alkalis it is soluble. In water sparingly soluble. 
Stability and Storage Conditions
85 
Mannitol is stable in the dry state and in aqueous solutions. The bulk material 
should be stored in a well closed container in a cool, dry place. 
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MAGNESIUM STEARATE  
Structural formula 
 
GENERAL DESCRIPTION
78
 
Nonproprietary Names  
 BP   : Magnesium stearate   
 USP NF : Magnesium stearate. 
Synonyms 
Hyqual, magnesium octadecanoate stearic acid magnesium salt. 
Chemical Name 
Octadecanoic acid magnesium salt. 
Empirical Formula 
C36H70 MgO4. 
Molecular weight 
591.27. 
Functional category 
Tablet and capsule lubricant. 
Moisture content 
3.85%. 
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Application in pharmaceutical formulation or technology 
 Magnesium stearate is widely used in cosmetics, food and pharmaceutical 
formulations.  It  is  primarily  used  as  lubricant  in  capsule  and  tablet  manufacture  at  
concentrations between 0.2-5.0 percent.
 
Description 
 Magnesium stearate is a fine, white, precipitated or milled, impalatable 
powder of low bulk density having a faint, characteristic odour and taste, the powder 
is greasy to touch and readily adheres to the skin. 
Typical properties 
Flowability    :    Poorly flowing, cohesive powder 
Density(bulk)  :   0.159g/cm
3 
Density(tapped) : 0. 286g/cm
3 
Melting point  :  88.5
0
C 
Solubility 
 Practically insoluble in ethanol, ethanol 95%, ether and water: slightly soluble 
in warm benzene and warm ethanol 95%. 
Stability and Storage Conditions 
 Magnesium stearate is stable and should be stored in a well – closed container 
in a cool and dry place. 
Safety
86
 
 Magnesium stearate is widely used as a pharmaceutical excipient and is 
generally regarded as being nontoxic following oral administration. However, oral 
consumption of large quantities may result in some laxative effect or mucosal 
irritation. Inhalation of magnesium stearate powder is harmful and has resulted in 
fatalities. 
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7. MATERIALS AND METHODS 
PRE FORMULATION STUDIES 
Preformulation testing is an investigation of physical and chemical properties 
of drug substances alone and when combined with pharmaceutical excipients. It is the 
first step in the rational development of dosage form. 
STANDARD CURVE OFLEVOFLOXACIN  
Potassium dihydrogen phosphate solution, 0.2M
87
 
27.218gm of potassium dihydrogen phosphate was dissolved in 1000ml 
distilled water in a volumetric flask. 
Sodium hydroxide solution, 0.2M 
 8gm of sodium hydroxide was dissolved in 1000ml distilled water and it gives 
0.2M solution. 
Preparation of pH 6.8 buffer 
Place 50.0ml of 0.2M potassium dihydrogen phosphate in a 200ml volumetric 
flask add 22.4ml of 0.2M sodium hydroxide and then make up with water upto 
volume.  
Preparation of levofloxacin stock solution 
100 mg of pure drug of Levofloxacin was dissolved in 100ml volumetric flask. 
The drug was shaked with 5ml methanol. For the above solution, add remaining 
amount was make up with 6.8pH Phosphate buffer. This solution contains 1000µg/ml 
of levofloxacin stock solution. Take 10ml from above solution in 100ml volumetric 
flask and make up with 6.8pH Phosphate buffer. This solution contains 100µg/ml of 
drug. From above solution take 1 ml in 10ml volumetric flask and make up with 6.8 
pH Phosphate buffer. From this solution pipette out 0.2 ml in 10ml volumetric flask 
add buffer. This gives 0.2µg/ml Solution. Similarly, preparing the 0.4ml, 0.6ml, 0.8ml 
and 1ml of solutions in 10ml volumetric flasks Resulting gives, 2µg/ml, 4µg/ml, 
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6µg/ml, 8µg/ml and 10µg/ml solutions. The concentrated solution scanned in UV-
Visible Spectrophotometer with absorption maximum is 298nm. 
STANDARD CURVE OF LEVOFLOXACIN 
Table No.6: Standard curve of Levofloxacin in Phosphate buffer (pH 6.8) 
S.No 
Concentration 
(μg/ml) 
Absorbance 
(298nm) 
1 0 0.00 
2 2 0.232 
3 4 0.465 
4 6 0.684 
5 8 0.926 
6 10 1.126 
 
 
 
 
Figure No.7: Standard curve of Levofloxacin in Phosphate buffer (pH 6.8) 
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METHOD OF PREPARATION 
PREPARATION OF LEVOFLOXACIN TABLETS: 
Direct Compression Technique: 
This method is used when the ingredients can be blended and placed in a tablet 
press to make a tablet without any of the ingredients having to be pre-processed. This 
requires the active ingredient to have appropriate physical and chemical properties, 
such as good compatibility and low stickiness. Direct compression is often preferred 
because of its simplicity and relatively low cost, but may not always be technically 
feasible. 
In this method, all the powder excipients are mixed thoroughly in a 
polyethylene bag. After proper mixing, the powder was punched into tablets. The 
weight of the tablet was 400mg and dose of the drug is 150mg
88
. 
Table No.7: Different Formulation of Levofloxacin Oral Dispersible Tablets 
S. 
No 
Formulation 
Code 
Drug 
mg 
SSG 
mg 
CCS 
mg 
CP 
mg 
Avicel 
PH102 
mg 
Mannitol 
mg 
Sodium 
Saccharin 
mg 
Magnesium 
Stearate mg 
Mint 
flavor 
mg 
1 FLOT-1 150 90 - - 100 45 10 5 q.s 
2 FLOT-2 150 - 90 - 100 45 10 5 q.s 
3 FLOT-3 150 - - 90 100 45 10 5 q.s 
4 FLOT-4 150 45 45 - 100 45 10 5 q.s 
5 FLOT-5 150 - 45 45 100 45 10 5 q.s 
6 FLOT-6 150 45 - 45 100 45 10 5 q.s 
7 FLOT-7 150 30 30 30 100 45 10 5 q.s 
 
Each Tablet wt – 400mg. 
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EVALUATION PARAMETERS 
PRECOMPRESSION STUDIES OF POWDER BLENDS 
Bulk density
89
 
Bulk density is the ratio between a given mass of powder or granules and its 
bulk volume. Accurately weighed quantity of granules was carefully transferred into 
100ml measuring cylinder, initial volume was measured and calculated according to 
the formula 
Bulk density = Mass / Volume 
Tapped density 
Tapped density is the ratio between a given mass of powder or granules and 
the constant or fixed volume of the powder or granules after tapping. Tapped density 
is determined by placing a graduated cylinder containing a known mass of granules 
and mechanical tapper apparatus, which is operated for a fixed number of taps until 
the powder bed volume has reached a minimum volume. Using the weight of the 
granules in the cylinder and this minimum volume, the tapped density may be 
computed.  
Tapped density =    Weight of granules/ Tapped volume of granules 
Angle of Repose
90
 
 Angle of repose is defined as the maximum angle possible between the surface 
of the pile of powder and horizontal plane. The angle of repose of the power or 
granules was determined by fixed funnel method to assess the flow property of the 
powder or granules. The manner in which stresses are transmitted through a bead and 
the beads response to applied stress are reflected in the various angles of friction and 
response. The most commonly used of this in angle of repose, which may be 
determined experimentally by number of methods(Table No.8). The method used to 
find  the  angle  of  repose  is  to  pour  the  powder  a  conical  on  a  level,  flat  surface  and  
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measure  the  included  angle  with  the  horizontal.  The  angle  of  repose  (θ) was 
calculated by using the following formula: 
θ = Tan-1 (h/r) 
Where, 
θ = Angle of repose, 
h = Height of the powder cone, 
r = Radius of the powder cone. 
Table No.8: Angle of Repose I.P limits 
S.No Angle of Repose Powder flow 
1 < 25 Excellent 
2 25 – 30 Good 
3 30 – 40 Passable 
4 > 40 Very poor 
 
Compressibility Index or Carr’s Index 
Carr’s Index is measured using the values of bulk density and tapped density 
(Table No.9). 
 The following equation is used to find the Carr’s Index, 
                                                          (TD-BD)  
                                          CI  =        × 100 
                                                               TD  
  
 Where, TD = Tapped density 
  BD = Bulk density 
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Table No.9: Carr’s Index I.P limits 
S.No Carr’s Index I.P Limits value 
1 Excellent <10 
2 Good 11 – 15 
3 Fair 16 – 20 
4 Possible 21 – 25 
5 Poor 26 – 31 
6 Very poor 32 – 37 
7 Very very poor >38 
 
Hausner’s Ratio 
It indicates the flow properties of the powder and ratio of Tapped density to 
the Bulk density of the powder or granules (Table No.10).The hausner’s ratio was 
calculated by using the following formula. 
Hausner’s Ratio = Tapped density/Bulk density 
Table No.10: Hausner’s RatioI.P Limits 
S. 
No 
Hausner’s Ratio I.P Limits value 
1 Excellent 1.00 – 1.11 
2 Good 1.1 – 1.18 
3 Fair 1.19 – 1.25 
4 Possible 1.26 -1.34 
5 Very poor 1.35 -1.45 
6 Very very poor >1.60 
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POSTCOMPRESSION STUDIES OF LEVOFLOXACIN TABLETS 
To design tablets and later to monitor tablets production, and quality, 
quantitative evaluation, assessments of tablets physical, chemical, and bioavailability 
properties must be made. 
             There are various standards that have been set in the various pharmacopoeias 
regarding the quality of pharmaceutical tablets. These include the diameter, thickness, 
weight variation, hardness, disintegration and dissolution characters. The diameters 
and shape depends on the die and punches selected for the compression of tablets. The 
remaining specifications assure that tablets do not vary from one production lot to 
another. The following standards or quality control tests should be carried out on 
compressed tablets: 
Hardness or Crushing strength Test
91
 
Hardness is a force required to break a tablet across a diameter. Hardness of 
the tablet was determined using the Monsanto hardness tester (The lower plunger was 
placed in contact with the tablet and a zero reading was taken. The plunger was then 
forced against a spring by tuning a threaded bolt until the tablet fractured. As the 
spring was compressed a pointer rides along a gauge in the barrel to indicate the force. 
The force required to break the tablet is measured in kilograms and a crushing 
strength of 4Kg is usually considered to be the minimum for satisfactory tablets. Oral 
tablets normally have a hardness of 4 to 10kg ; however, hypodermic and chewable 
tablets are usually much softer (3 kg) and some sustained release tablets are much 
harder (10 -20 kg)
11
. 
Thickness Test 
The thickness of the tablet is mostly related to the tablet hardness can be uses 
as initial control parameter. Ten tablets were randomly selected from each tablet 
thickness was determined using a Vernier calliper and the reading was recorded in 
millimeters. 
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Friability Test
92 
Friability  is  the  loss  of  weight  of  tablet  in  the  container/package,  due  to  
removal  of  fine  particles  from  the  surface.  It  is  usually  measured  by  the  use  of  the  
Roche friabilator. The pre-weighed tablets were placed in the friabilator which was 
then operated for 100rpm, then dusted and reweighed. The Conventional compressed 
tablets that lose less than 0.5-1.0% of their weight are generally considered 
acceptable.   The percent friability was determined using the following formula. 
 
        
 
Where, 
W 1 = Weight of ten tablets before test  
W2  = Weight of ten tablets after test 
Weight variation test 
This is an important in-process quality control test to be checked frequently 
(every half an hour). Corrections were made during the compression of tablets. Any 
variation in the weight of tablet (for any reason) leads to either under medication or 
overdose. Therefore, every tablet in each batch should have a uniform weight. Twenty 
tablets of each formulation were selected at random and weighed individually. The 
weight of individual tablets was noted. Average weight was calculated from the total 
weight of all tablets. The individual weights were compared with the average weight. 
Not  more  than  two  of  the  tablets  must  differ  from  the  average  weight  by  not  more  
than the percentages stated in table below. The percentage deviation was calculated 
by using the following formula. 
      Individual weight - Average weight 
Percentage Deviation =  
     Average weight 
             Friability    =    x100  
 
 
(W1-W2) 
W1 
x 100 
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Table No.11: Weight variation Tolerances for uncoated Tablets 
S. 
No 
Average weight of Tablets(mg) Maximum % difference allowed 
1 130 or less ± 10 
2 130-324 ±7.5 
3 More than 324 ±5 
 
Estimation of Drug Content
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The term "Uniformity of dosage unit" is defined as the degree of uniformity 
for substance among dosage units. The test for content uniformity is based on the 
assay of the active medicament of content uniformity is necessary the quantity of the 
active medicament is within the limit in the formulation. 
Ten tablets from each formulation were powdered. The powder equivalent to 
150mg of Levofloxacin was weighed and dissolved in Distilled water  in 100ml 
standard flasks. From this suitable dilution was prepared and the solution was 
analyzed at 298 nm using UV double beam spectrophotometer . 
Disintegration time study 
The test was carried out on six tablets using distilled water at 37
0
C + 2
0
C was 
used as disintegration media and the time in second taken for complete disintegration 
of the tablet with no palatable mass remaining in the apparatus was measured in 
seconds. 
Wetting time study 
A piece of tissue paper folded twice was placed in a small Petri dish (internal 
diameter = 6.5cm) containing 5 ml of distilled water. A tablet was placed on the 
paper, and the time for complete wetting of the tablet was measured in seconds. All 
the post compression parameters results are shown in table 14.  
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In vitro drug release study 
In vitro release studies were carried out by using USP paddle dissolution test 
apparatus. 900ml of Phosphate buffer (pH 6.8)was taken in the dissolution vessel and 
the temperature of the medium was maintained at 37±0.5
o
C. 100rpm was maintained, 
1 ml of sample was withdrawn at predetermined time intervals for 0, 1, 3, 6, 9, 12 and 
15mints. The same volume of the fresh medium was replaced. The samples were 
analyzed at 298nm by using a UV spectrophotometer. The dissolution data obtained 
were plotted as percentage drug release versus time. 
FT-IR studies
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It was used to study the interactions between the drug and superdisintegrants. 
The drug and superdisintegrants must be compatible with one another to produce a 
product stable, efficacious and easy to administer and safe.  
IR spectral analysis for drug, superdisintegrants was carried out. If there is no 
change in peaks of mixture when compared to pure drug, it  indicates the absence of 
interactions. 
Stability Studies 
 The concentration of an active ingredient of any formulation may decrease 
with increase in temperature and time. This will lead to decrease the potency of the 
product. Stability study in different temperatures should be carried out to predict the 
stability of the formulations. 
 Stability studies were aimed at determining the result of aging and storage 
under various conditions on the formulated Fast dissolving tablets. Stability studies 
are used to find out whether any chemical degradation of Levofloxacin formulations 
take place or not. The formulated tablets were stored at 4
o± 2oC (in refrigerator), 27o± 
2
o
C (in room temperature) and 45
o
C ± 2oC (in accelerated stability chamber) for 45 
days. Three tablets were taken from all the stored samples at the intervals of 15
th
, 30
th
 
and 45
th
 days and analysed for drug content and in vitro release studies were carried 
out to determine the percentage of Levofloxacin released . 
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9. RESULTS AND DISCUSSIONS 
Pre Formulation Studies 
The present study was undertaken to formulate Levofloxacin  oral dispersible  
tablets with three polymers namely Crospovidone, CCS and SSG and in combination 
of three Superdisintegrants and by dry granulation technique. Before compression of 
the  granules  physical  characters  such  as,  bulk  density,  tapped  density,   angle  of  
repose, compressibility index and Hausner ratio were determined and tabulated in the 
Table12. Then the granules were compressed into tablets and then evaluated. The 
results are presented in Table 13. 
PRECOMPRESSION STUDIES OF GRANULES 
Bulk density 
The packing properties of the drugs and their formulations widely depend 
upon bulk density. It has been stated that bulk density values less than 1.2gm/cm
3 
indicate good flow and values greater than 1.5 gm/cm
3
 indicate poor flow. 
From the results it can be seen that the bulk density values are less than 
1.2gm/cm
3
.  This  indicates  good flow characteristics  of  the  granules.  Values  showed 
Table No.12. 
Tapped density 
From the above results it can be seen that the Tapped density values indicate 
good flow characteristics of the granules. Values showed Table No.12. 
Angle of Repose 
Angle of repose less than or equal to 40
o
C indicates free flowing properties of 
thegranules. However angle of repose greater than 40
o
Cindicates poor flow of 
material. 
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It  can  be  observed  from  above  table  that  the  angle  of  repose  for  various  
batches of thegranules is found to be less than 40
o
C, it indicates good flow properties 
of the granules. Values showed Table No.12. 
Compressibility Index or Carr’s Index 
Carr’s Index less than or equal to <10 indicates free flowing properties of the 
granules. However Carr’s Index greater than <10 indicates poor flow of material. 
It can be observed from above table that the Carr’s Index for various batches 
of  thegranules  is  found to  be  less  than  >10;  it  indicates  good flow properties  of  the  
granules. Values showed Table No.12. 
Hausner’s Ratio 
Hausner’s Ratio less than or equal to 1.069 indicates free flowing properties of 
thegranules. However Hausner’s Ratio greater than 1.35 indicates poor flow of 
material. 
It can be observed from above table that the Hausner’s Ratio for various 
batches of the granules is found to be less than 1.122; it indicates good flow properties 
of the granules. 
Table no – 12 :Precompression studies of powder blend 
S. 
No 
Formulations 
Bulk 
Density 
(gm/ml) 
Tapped 
Density 
(gm/ml) 
Angle of 
Repose 
(θ) 
Carr's 
Index 
(%) 
Hausner's 
Ratio 
1 FLOT-1 0.334 0.375 32.26 10.93 1.122 
2 FLOT-2 0.346 0.372 34.15 6.98 1.075 
3 FLOT-3 0.328 0.362 33.82 9.39 1.103 
4 FLOT-4 0.312 0.333 31.38 6.30 1.067 
5 FLOT-5 0.333 0.368 35.07 9.51 1.105 
6 FLOT-6 0.352 0.384 35.07 8.33 1.090 
7 FLOT-7 0.326 0.354 39.48 7.90 1.085 
 
66 
EVALUATION OF LEVOFLOXACIN ORAL DISPERSIBLE TABLETS 
The compressed tablets were evaluated for physical properties and the results 
are tabulated in Table no -13 
Hardness Test 
 The hardness of the tablet various batches were determined. The various 
batches of the tablets of hardness values are found within limits and it indicates good 
strength of the oral dispersible tablets. Values showed Table. No 13. 
Thickness Test 
The tablets mean thicknesses were almost uniform in the all formulations and 
were found to be in the range of 0.37mm. Values showed Table. No 13. 
Friability Test 
The oral dispersibletablets friability values are found to be less than 1% in all 
cases and considered to be satisfactory. Values showed Table. No 13. 
Weight variation test 
All this oral dispersibletablets passed weight variation test as the % weight 
variation was within the pharmacopoeia limits. The weight of the all tablets was found 
to be uniform with low standard deviation values. Values showed Table. No 13. 
Estimation of Drug Content 
Drug content of all the batches are within the acceptable range which shows 
the proper mixing of the drug with the excipients. Values showed Table. No 13. 
Disintegration time study 
The disintegration time (D.T) of all formulations is shown in the Table No.14 
and Figure No.8. 
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Table No.13: Postcompression studies of Levofloxacin oral dispersible Tablets 
S. 
No 
Formulations 
Hardness 
Test 
(kg/cm) 
Thickness 
Test (cm) 
Friability 
Test (%) 
% of 
Weight 
variation 
test 
Estimation 
of Drug 
Content % 
1 FLOT-1 2.45 0.37 0.164 99.7 98.12 
2 FLOT-2 2.34 0.37 0.228 99.2 96.29 
3 FLOT-3 3.42 0.37 0.236 99.8 97.54 
4 FLOT-4 2.92 0.37 0.267 99.8 97.27 
5 FLOT-5 2.65 0.37 0.224 99.6 96.48 
6 FLOT-6 3.23 0.37 0.254 99.5 98.34 
7 FLOT-7 2.86 0.37 0.253 99.9 98.84 
 
 
 
Table No.14: Postcompression studies of Levofloxacin oral dispersible Tablets 
 
S.No Formulations Disintegration time (sec) Wetting time(sec) 
1 FLOT-1 25 17 
2 FLOT-2 23 16 
3 FLOT-3 32 17 
4 FLOT-4 22 15 
5 FLOT-5 25 15 
6 FLOT-6 23 16 
7 FLOT-7 20 14 
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Figure no – 8 :Disintegration time 
Wetting time study 
The wetting time (W.T) of all formulations is shown in the Table No.14. 
 
Figure no – 9 :Wetting time 
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IR Spectral analysis 
The IR Spectral studies of Pure levofloxacine,  Crospovidone, Sodium starch 
glycolate  and  CCS   were  carried  out  to  study  the  interaction  between  the  drug  and  
super disintegrants used.It showed that IR spectrum of pure Levofloxacin and  
superdisintegrants  were similar fundamental peaks and patterns. The results proved 
that there were no significant interactions between the drug and super disintegrants. 
The results are shown in Figures:10 - 20. 
 
Figure No.10: FTIR spectrum of Levofloxacin  
 
 
Figure No.11: FTIR spectrum of SSG 
70 
 
 
 
 
 
 
 
 
Figure No.12: FTIR spectrum of CCS 
 
 
Figure No.13: FTIR spectrum of CP 
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Figure No.14: FTIR spectrum of Levofloxacin and SSG 
 
 
 
 
Figure No.15: FTIR spectrum of Levofloxacin and CCS 
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Figure No.16: FTIR spectrum of Levofloxacin and CP 
 
 
 
Figure No.17: FTIR spectrum of Levofloxacin +SSG+CCS 
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Figure No.18: FTIR spectrum of Levofloxacin +CCS+CP 
 
 
 
Figure No.19: FTIR spectrum of Levofloxacin +SSG+CP 
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Figure No.20: FTIR spectrum of Levofloxacin +SSG+CCS+CP 
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IN-VITRO DRUG RELEASE STUDY 
Tablets of all the formulations were subjected for invitro release studies .the 
results are presented in Table no. (21-28). 
Table No.15: Formulations-1 (FLOT-1) 
S. 
No 
Time 
(mints) 
Absorbance 
(298nm) 
Concentration 
(µg/ml) 
Amount of drug 
release 
(in 900 ml) 
% of drug 
release 
1 0 0.000 0.000 0.000 0.000 
2 1 0.125 1.078 9.710 6.47 
3 3 0.496 4.350 39.15 26.61 
4 6 0.684 6.000 54.00 36.00 
5 9 0.923 8.096 72.86 48.57 
6 12 1.249 10.956 98.605 65.73 
7 15 1.723 15.114 136.02 90.68 
 
 
Figure No.21:Formulations-1(FLOT-1) 
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Table No.16: Formulations-2 (FLOT-2) 
S. 
No 
Time 
(mints) 
Absorbance 
(298nm) 
Concentration 
(µg/ml) 
Amount of drug 
release 
(in 900 ml) 
% of drug 
release 
1 0 0.000 0.000 0.000 0.000 
2 1 0.096 0.842 7.578 5.05 
3 3 0.392 3.438 30.94 20.63 
4 6 0.592 5.192 46.73 31.15 
5 9 0.879 7.710 69.39 46.26 
6 12 1.152 10.10 90.94 60.63 
7 15 1.674 14.68 132.1 88.10 
 
 
Figure No.22: Formulation-2 (FLOT-2) 
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Table No.17: Formulations-3 (FLOT-3) 
S. 
No 
Time 
(mints) 
Absorbance 
(298nm) 
Concentration 
(µg/ml) 
Amount of drug 
release 
(in 900 ml) 
% of drug 
release 
1 0 0.000 0.000 0.000 0.000 
2 1 0.082 0.719 6.473 4.315 
3 3 0.364 3.192 28.73 19.15 
4 6 0.562 4.929 44.36 29.57 
5 9 0.853 7.482 67.34 44.89 
6 12 1.106 9.701 87.31 58.21 
7 15 1.583 13.88 124.9 83.31 
 
 
Figure No.23:Formulations-3 (FLOT-3) 
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Table No.18: Formulations-4 (FLOT-4) 
S. 
No 
Time 
(mints) 
Absorbance 
(298nm) 
Concentration 
(µg/ml) 
Amount of drug 
release 
(in 900 ml) 
% of drug 
release 
1 0 0.000 0.000 0.000 0.000 
2 1 0.132 1.157 10.42 6.947 
3 3 0.521 4.570 41.13 27.42 
4 6 0.694 6.087 54.78 36.52 
5 9 0.942 8.263 74.36 49.57 
6 12 1.256 11.01 99.15 66.10 
7 15 1.763 15.46 139.1 92.78 
 
 
Figure No.24:Formulations-4 (FLOT-4) 
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Table No.19: Formulations-5 (FLOT-5) 
S. 
No 
Time 
(mints) 
Absorbance 
(298nm) 
Concentration 
(µg/ml) 
Amount of drug 
release 
(in 900 ml) 
% of drug 
release 
1 0 0.000 0.000 0.000 0.000 
2 1 0.108 0.947 8.526 5.684 
3 3 0.405 3.552 31.97 21.31 
4 6 0.612 5.368 48.31 32.21 
5 9 0.894 7.842 70.57 47.05 
6 12 1.168 10.24 92.21 61.47 
7 15 1.686 14.78 133.1 88.73 
 
 
Figure No.25:Formulations-5 (FLOT-5) 
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Table No.20: Formulations-6 (FLOT-6) 
S. 
No 
Time 
(mints) 
Absorbance 
(298nm) 
Concentration 
(µg/ml) 
Amount of drug 
release 
(in 900 ml) 
% of drug 
release 
1 0 0.000 0.000 0.000 0.000 
2 1 0.128 1.122 10.10 6.736 
3 3 0.514 4.508 40.57 27.05 
4 6 0.674 5.912 53.21 35.47 
5 9 0.926 8.122 73.10 48.73 
6 12 1.235 10.83 97.50 65.00 
7 15 1.745 15.30 137.7 91.84 
 
 
Figure No.26:Formulations-6 (FLOT-6) 
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Table No.21: Formulations-7 (FLOT-7) 
S. No 
Time 
(mints) 
Absorbance 
(298nm) 
Concentration 
(µg/ml) 
Amount of 
drug release 
(in 900 ml) 
% of drug 
release 
1 0 0.000 0.000 0.000 0.000 
2 1 0.138 1.210 10.89 7.263 
3 3 0.542 4.754 42.78 28.52 
4 6 0.696 6.105 54.94 36.63 
5 9 0.957 8.394 75.55 50.36 
6 12 1.278 11.21 100.8 67.26 
7 15 1.826 16.01 144.1 96.10 
 
 
Figure No.27:Formulations-7 (FLOT-7) 
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Table No.22:Comparative dissolution study of different formulations with various 
ratios of Super disintegrants 
S. 
No 
Time 
(mints) 
% of drug 
release 
(FLOT-1) 
% of drug 
release 
(FLOT-2) 
% of drug 
release 
(FLOT-3) 
% of drug 
release 
(FLOT-4) 
% of drug 
release 
(FLOT-5) 
% of drug 
release 
(FLOT-6) 
% of drug 
release 
(FLOT-7) 
1 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1 6.47 5.05 4.315 6.947 5.684 6.736 7.263 
3 3 26.61 20.63 19.15 27.42 21.31 27.05 28.52 
4 6 36.00 31.15 29.57 36.52 32.21 35.47 36.63 
5 9 48.57 46.26 44.89 49.57 47.05 48.73 50.36 
6 12 65.73 60.63 58.21 66.10 61.47 65.00 67.26 
7 15 90.68 88.10 83.31 92.78 88.73 91.84 96.10 
 
 
Figure No.28A: Comparative dissolution study of different formulations with 
various ratios of polymers 
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Figure No.28 (B): Comparative dissolution study of different formulations with 
various ratios of Super disintegrants 
 
STABILITY STUDIES 
 Levofloxacin oral dispersible tablets (all 7 formulations) were stored at 
refrigerated temperature (4
°
C±2
°
C), room temperature (27
°
C±  2
°
C) and in 
programmable envirnomental test chamber (45
°
C± 2
°
C) for 45 days. 
 At the end of 15, 30 and 45 days of storage, the controlled release tablets were 
observed for changes in physical appearance analyzed for drug content and subjected 
to invitro release studies and the result was presented in Table No 23 - 30 
 There was no change in the percentage release of Levofloxacin    from all the 
formulations stored at different temperatures upto 45 days. Tablet evaluation tests 
were carried out and there were no deviations in all the tests and all are within the 
limits. It showed that all the formulations are physically stable. There was no change 
in the drug content Table No23 and invitro drug release Table No 24-30. It showed 
that all the formulations are chemically stable. 
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Table No -23 
DRUG CONTENT ESTIMATION AFTER STORING AT DIFFERENT TEMPERATURES 
 
 
No 
F
o
rm
u
la
ti
o
n
 
DRUG CONTENT* 
4
O
C± 2OC 27OC± 2OC 45OC± 2OC 
15
th
 days 30
th
 days 45
th
 days 15
th
 days 30
th
 days 45
th
 days 15
th
 days 30
th
 days 45
th
 days 
1 F1 98.12 98.11 98.14 98.10 98.11 98.12 98.13 98.15 98.12 
2 F2 96.29 96.27 96.28 96.31 96.31 96.30 96.29 96.28 96.27 
3 F3 97.54 97.56 97.53 97.52 97.51 97.55 97.54 97.52 97.54 
4 F4 97.27 97.28 97.24 97.28 97.29 97.24 97.28 97.24 97.27 
5 F5 96.48 96.49 96.47 96.45 96.45 96.46 96.48 96.49 96.48 
6 F6 98.34 98.32 98.31 98.34 98.33 98.35 98.32 98.34 98.35 
7 F7 98.84 98.85 98.87 98.82 98.83 98.81 98.85 98.86 98.84 
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Table No –24 
 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION –F1 
 
 
S
.N
o
 
T
im
e 
in
 
(m
ts
) 
0 days 
PERCENTAGE DRUG RELEASE (%)*  
15
th
 days 30
th
 days 45
th
 days 
4°C± 2°C 27°C ± 2°C 45°C± 2°C 4°
 
C± 2°C 27°C± 2°
 
C 45°C± 2°C 4°C± 2°C 27°C± 2°
 
C 45°C± 2°C 
1 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1 6.47 6.44 6.46 6.45 6.48 6.47 6.49 6.44 6.48 6.45 
3 3 26.61 26.64 26.62 26.63 26.59 26.60 26.62 26.63 26.64 26.61 
4 6 36.00 36.01 36.03 36.02 36.01 36.04 36.02 36.04 36.00 36.05 
5 9 48.57 48.59 48.57 48.58 48.55 48.56 48.57 48.54 48.59 48.58 
6 12 65.73 65.72 65.71 65.74 65.72 65.73 65.76 65.75 65.74 65.73 
7 15 90.68 90.69 90.68 90.70 90.66 90.65 90.68 90.69 90.69 90.67 
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Table No- 25 
 
STABILITY STUDIES OF  DISSOLUTION PROFILE OF FORMULATION –F2 
 
 
S
. 
N
o
 
T
im
e 
in
 
(m
ts
) 
0 days 
PERCENTAGE DRUG RELEASE (%)*  
15
th
 days 30
th
 days 45
th
 days 
4°C± 2°C 27°C ± 2°C 45°C± 2°C 4°
 
C± 2°C 27°C± 2°
 
C 45°C± 2°C 4°C± 2°C 27°C± 2°
 
C 45°C± 2°C 
1 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1 5.05 5.04 5.06 5.03 5.02 5.07 5.05 5.04 5.07 5.05 
3 3 20.63 20.62 20.61 20.64 20.61 20.65 20.63 20.64 20.62 20.63 
4 6 31.15 31.12 31.14 31.16 31.17 31.14 31.16 31.15 31.14 31.12 
5 9 46.26 46.28 46.26 46.25 46.22 46.23 46.24 46.25 46.28 46.27 
6 12 60.63 60.61 60.62 60.65 60.66 60.61 60.62 60.63 60.64 60.63 
7 15 88.10 88.11 88.12 88.10 88.09 88.08 88.11 88.12 88.01 88.10 
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Table No –26 
 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION –F3 
 
 
S
.N
o
 
T
im
e 
in
 (
m
ts
)  
0 days 
PERCENTAGE DRUG RELEASE (%)*  
15
th
 days 30
th
 days 45
th
 days 
4°C± 2°C 27°C ± 2°C 45°C± 2°C 4°C± 2°C 27°C± 2°
 
C 45°C± 2°C 4°C± 2°C 27°C± 2°
 
C 45°C± 2°C 
1 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1 4.315 4.320 4.318 4.316 4.312 4.310 4.314 4.313 4.312 4.315 
3 3 19.15 19.16 19.15 19.14 19.11 19.12 19.16 19.18 19.15 19.12 
4 6 29.57 29.54 29.53 29.56 29.58 29.59 29.58 29.56 29.57 29.58 
5 9 44.89 44.88 44.87 44.84 44.90 44.91 44.84 44.86 44.85 44.89 
6 12 58.21 58.19 58.20 58.26 58.25 58.25 58.23 58.20 58.24 58.22 
7 15 83.31 83.29 83.28 83.32 83.33 83.31 83.34 83.33 83.35 83.34 
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Table No – 27 
 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION –F4 
 
 
S
.N
o
 
T
im
e 
in
 (
m
in
ts
) 
0 days 
PERCENTAGE DRUG RELEASE (%)*  
15
th
 days 30
th
 days 45
th
 days 
4°C± 2°C 27°C ± 2°C 45°C± 2°C 4°
 
C± 2°C 27°C± 2°C 45°C± 2°C 4°C± 2°C 27°C± 2°C 45°C± 2°C 
1 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1 6.947 6.942 6.945 6.945 6.942 6.939 6.940 6.944 6.949 6.947 
3 3 27.42 27.41 27.40 27.41 27.43 27.42 27.49 27.45 27.41 27.43 
4 6 36.52 36.53 36.53 36.50 36.51 36.55 36.54 36.53 36.51 36.54 
5 9 49.57 49.56 49.58 49.57 49.56 49.52 49.53 49.58 49.59 49.56 
6 12 66.10 66.13 66.12 66.11 66.10 66.09 66.14 66.11 66.13 66.15 
7 15 92.78 92.79 92.78 92.77 92.80 92.78 92.77 92.76 92.75 92.74 
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Table No - 28 
 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION –F5 
 
S
.N
o
 
T
im
e 
in
 (
m
ts
) 
0 days 
PERCENTAGE DRUG RELEASE (%)*  
15
th
 days 30
th
 days 45
th
 days 
4°C± 2°C 27°C ± 2°C 45°C± 2°C 4°
 
C± 2°C 27°C± 2°C 45°C± 2°C 4°C± 2°C 27°C± 2°C 45°C± 2°C 
1 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1 5.684 5.682 5.679 5.646 5.684 5.676 5.682 5.681 5.680 5.683 
3 3 21.31 21.32 21.34 21.33 21.35 21.28 21.31 21.30 21.33 21.32 
4 6 32.21 32.22 32.23 32.20 32.19 32.24 32.23 32.21 32.22 32.19 
5 9 47.05 47.04 47.06 47.02 47.01 47.03 47.07 47.08 47.09 47.05 
6 12 61.47 61.42 61.46 61.48 61.46 61.44 61.43 61.47 61.48 61.49 
7 15 88.73 88.74 88.76 88.75 88.71 88.72 88.73 88.74 88.76 88.77 
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Table No – 29 
 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION –F6 
 
 
S
.N
o
 
T
im
e 
in
 (
m
ts
) 
0 days 
PERCENTAGE DRUG RELEASE (%)*  
15
th
 days 30
th
 days 45
th
 days 
4°C± 2°C 27°C ± 2°C 45°C± 2°C 4°
 
C± 2°C 27°C± 2°C 45°C± 2°C 4°C± 2°C 27°C± 2°C 45°C± 2°C 
1 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1 6.736 6.745 6.732 6.754 6.727 6.721 6.741 6.752 6.736 6.739 
3 3 27.05 27.04 27.06 27.03 27.01 27.04 27.06 27.04 27.05 27.01 
4 6 35.47 35.44 35.48 35.49 35.47 35.46 35.46 35.48 35.44 35.49 
5 9 48.73 48.72 48.76 48.77 48.75 48.76 48.73 48.72 48.71 48.75 
6 12 65.00 65.02 65.05 65.02 65.00 65.01 65.02 65.03 65.04 65.01 
7 15 91.84 91.83 91.85 91.86 91.82 91.82 91.86 91.87 91.83 91.82 
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Table No - 30 
 
STABILITY STUDIES OF DISOLUTION PROFILE OF FORMULATION –F7 
 
 
S
.N
o
 
T
im
e 
in
 (
m
ts
) 
0 days 
 
PERCENTAGE DRUG RELEASE (%)* 
 
15
th
 days 30
th
 days 45
th
 days 
4°C± 2°C 27°C ± 2°C 45°C± 2°C 4°C± 2°C 27°C± 2°C 45°C± 2°C 4°C± 2°C 27°C± 2°C 45°C± 2°C 
1 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1 7.263 7.252 7.251 7.268 7.272 7.282 7.264 7.263 7.268 7.262 
3 3 28.52 28.51 28.53 28.52 28.54 28.51 28.54 28.56 28.58 28.55 
4 6 36.63 36.61 36.62 36.63 36.65 36.66 36.64 36.64 36.62 36.61 
5 9 50.36 50.32 50.38 50.37 50.34 50.33 50.36 50.31 50.32 50.34 
6 12 67.26 67.24 67.26 67.28 67.27 67.25 67.24 67.29 67.28 67.26 
7 15 96.10 96.18 96.10 96.09 96.10 96.11 96.12 96.14 96.17 96.18 
 
 
 
92 
DISCUSSION 
Oral dispersible tablets of Levofloxacin were prepared by directcompression 
method. The prepared Oral dispersible tablets are round in shape. Microscopic 
examination of tablets from each formulation batch showed circular shape with no 
cracks. The fourier transform infra-red analysis was conducted for the surface 
structure characterization. FTIR spectrum of the formulated Oral dispersible tablets, 
pure drug and super disintegrants was recorded. The Fourier Transform Infrared 
Spectroscopy study reveals that there is no interaction between the super disintegrants 
and pure drug.  
Bulk density (0.312 to 0.352 gm/cm
3
) and Tapped density (0.333 to 0.384 
gm/cm
3
) values are within the limits, indicating that the powder blends have the 
required flow property for direct compression. The values obtained for angle of 
repose  for  all  formulations  are  tabulated  in  table  the  values  were  found to  be  in  the  
range from 31.38-39.48
0
C. This indicates good flow property of the powder blend. 
Compressibility index (6.30 to 10.93) and Hausner’s ratio (1.067 to 1.122) values are 
within the limits, indicating that the powder blends have the required flow property 
for direct compression. 
The hardness of the Oral dispersible tablet various batches were determined. 
The various batches of the Oral dispersible tablets of hardness values are found within 
limits and it indicates good strength of the Oral dispersible tablets. Tablet mean 
thicknesses were almost uniform in the all  formulations and were found to be in the 
range of 0.37mm. Friability values are found to be less than 1% in all cases and 
considered to be satisfactory. All this tablets passed weight variation test as the % 
weight variation was within the pharmacopoeia limits. Drug content of all the batches 
are within the acceptable range which shows the proper mixing of the drug with the 
excipients. 
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The in vitro drug release profile of tablets from each batch (FLOT-1 to FLOT-
7) was carried in phosphate buffer (pH 6.8) for 15 mints by using paddle type of 
device. From the in vitro dissolution data, FLOT-7 formulation was found that the 
drug release is best and the cumulative % of drug release was 96.10 % respectively, 
when compared to other formulation. 
 All the formulations were subjected for stability studies for 45 days at 
different temperatures such as room temperature, fridge temperature and acclerated 
temperature (45°C±2°C). At 15 days interval upto 45 days, the drug content and 
dissolution studies were carried out. There was no significant change in the drug 
content and invitro drug release. 
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9. SUMMARY AND CONCLUSION 
 Oral dispersible Tablets of Levofloxacin were prepared with two different 
superdisintegrants and evaluation of blend powder, tablets evaluation studies, IR 
spectral studies, dissolution studies and stability studies were performed .The 
summary are presented. 
v Preformulation  studies  such  as  angle  of  repose,  bulk  density,  tapped  density,  
compressibility index and hausner ratio were performed and the results 
showed that all the parameters are within the acceptable limits.  
v Tablets were prepared by direct compression method and evaluated for general 
appearance, hardness test, uniformity of weight, friability, wetting time, 
disintegration time, drug content estimation and in vitro release study. All the 
formulations were found to be good appearance without showing any 
chipping, capping and sticking defects and all other parameters were passed 
the test. 
v IR spectroscopic studies indicated that the drug is compatible with all the  
polymers and there was no drug-polymer interaction.  
v When comparing all the formulations, F7 shows a better drug release of 
96.10%  at the end of 15 minutes.  
v All the formulations were subjected for stability studies for 45 days at 
different temperatures such as room temperature, fridge temperature and 
accelerated temperature (45°C±2°C). At 15 days interval upto 45 days, the 
drug content and dissolution studies were carried out. There was no significant 
change in the drug content and invitro drug release. 
The main objective of the present study was to develop Oral dispersible tablet 
formulation containing 150mg of Levofloxacin for the treatment of a number of 
infections including infection of Joints and bones, respiratory tract infections, urinary 
tract infections, skin structural infections and typhoid fever etc. In the present work it 
has been observed from all formulations of precompression and post compression 
studies were given within the limit of values. The in vitro dissolution  data,  FLOT-
7(combination of different superdisintegrants) formulation was found that the drug 
release is best and the cumulative % of drug release was 96.10 % respectively, when 
compared to other formulation. 
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